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Abstract  approved: 
Vaccinia  virus  encodes  at  least  eight  proteins  that  are 
modified  post-translationally  by  the  addition  of  a  16-carbon 
saturated  fatty  acid  through  thioester  linkage  to  cysteine 
residues.  This  is  referred  to  as  palmitylation  of  proteins.  The 
purpose  of  this  work  was  to  gain  an  understanding  of 
palmitylation,  focusing  on  what  defined  the  substrate  for  the 
modification,  and  the  biological  relevance  of  protein 
palmitylation  in  the  vaccinia  virus  life  cycle. 
A  systematic  approach  was  taken  to  identify  the  genes  in 
vaccinia  virus  that  encode  these  proteins.  We  found  that  vaccinia 
virus  palmitylproteins  are  of  the  "late"  temporal  class,  associate 
with  intracellular  membranes,  and  are  specific  for  a  particular 
form  of  the  infectious  virion.  These  criteria  were  used  to  narrow 
the  number  of  genes  expressed  by  vaccinia  virus  that  potentially 
encode  palmitylproteins.  The  "candidate"  palmitylprotein  genes 
were  cloned  and  transiently  expressed  in  mammalian  tissue 
culture  cells  and  analyzed  for  incorporation  of  palmitic  acid.  In 
addition  to  three  previously  identified  vaccinia  virus 
palmitylproteins,  three  new  palmitylproteins  were  identified.  The 
six  known  palmitylprotein  genes  were  mutated  to  determine  the 
site  of  modification,  leading  to  the  identification  of  the 
modification  site  for  four  of  the  six  proteins. 
One  of  the  proteins,  p37,  was  analyzed  further  for  biological 
significance  of  the  palmitate  modification.  A  recombinant 
Redacted for Privacyvaccinia  virus  was  constructed  that  did  not  express  the  wild-type 
palmitylated  form  of  p37,  but  expressed  a  nonpalmitylated  form 
of  the  protein  instead.  This  virus  was  severely  inhibited  from 
proceeding  past  a  particular  morphogenetic  stage,  leading  to  an 
attenuated  phenotype  in  tissue  culture  systems.  Although  the 
expression  of  the  nonpalmitylated  protein  appeared  normal 
compared  to  the  wild-type  protein,  the  lack  of  the  palmityl 
moiety  resulted  in  the  loss  of  a  targeting  signal  that  directed  the 
protein  to  its  normal  intracellular  location. 
By  this  work,  significant  contributions  have  been  made 
toward  understanding  the  process  of  protein  palmitylation.  We 
have  identified,  at  least  for  vaccinia  virus,  primary  structural 
determinants  specifying  the  modification,  leading  to  the 
identification  of  a  palmitylation  motif.  Considering  the 
attenuated  phenotype  of  the  mutant  virus,  our  conclusion  is  that 
palmitylation  is  necessary  for  biological  function,  at  least  for 
p37. ©Copyright  by  Douglas W.  Grosenbach  
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1.1  Introduction 
Post-translational  processing  of  vaccinia  virus  proteins  has 
been  proven  to  be  a  common  mechanism  for  exerting  regulatory 
control  of  function  or  targeting  to  subcellular  and/or  subviral 
structures.  Fatty  acylation,  most  commonly  observed  as  the 
addition  of  myristate  or  palmitate,  occurs  on  numerous  vaccinia 
proteins  and  affects  each  in  a  distinct  manner.  Labeling  of 
vaccinia-infected  cells  with  tritiated  myristic  or  palmitic  acids 
demonstrates  that  vaccinia  encodes  at  least  six  myristylproteins 
and  as  many  as  eight  palmitylproteins.  Where  investigated,  each 
of  these  proteins  has  been  demonstrated  to  play  important  roles 
in  the  virus  life  cycle.  Likewise,  in  each  case  studied,  the  fatty 
acyl  modification  greatly  influences  the  function  and/or 
biological  activity  of  the  protein. 
1.1.1  Overview  of  the  Vaccinia  Life  Cycle 
Vaccinia  virus  (VV)  is  the  most  extensively  characterized 
member  of  the  Orthopoxvirus  genus  of  the  Poxviridae  family (61). 
Its  role  as  a  vaccine  in  the  eradication  of  smallpox  represents  one 
of  the  major  achievements  in  medicine.  Although  smallpox 
vaccines  are  no  longer  necessary,  VV  is  widely  used  as  a 
molecular  and  cellular  biology  tool  as  well  as  in  the  development 
of  recombinant  vaccines.  To  enhance  or  optimize  VV  for  these 
purposes,  basic  research  on  the  virus  itself  remains  a  major  area 
of  interest.  Current  research  topics  include 
structure/morphogenesis,  replication/resolution  of  the  genome, 
transcriptional  regulation,  enzymology,  immune  modulation,  and 
protein  processing. 
VV  is  a  large,  double-stranded  DNA  virus  with  a  broad 
mammalian  host  range.  Its  entire  life  cycle  is  carried  out  in  the 3 
cytoplasm  of  the  host,  with  little  or  no  requirement  for  the  host 
cell  nucleus  (Figure  1.1).  Upon  entry  into  the  cell,  the  virion  core 
is  partially  uncoated,  allowing  transcription  of  the  early  class  of 
genes.  Their  products  are  involved  in  genome  replication  and  as 
transcription  factors  for  the  intermediate  class  of  genes.  The  VV 
genome  is  composed  of  a  nearly  200  kilobasepair  linear double-
stranded  DNA  molecule  with  potential  to  encode  more  than  200 
polypeptides  (32). 
VV  open  reading  frames  are  designated  alphanumerically. 
Digestion  of  VV  genomic  DNA  with  the  restriction  enzyme  Hindlll 
generates 'sixteen  fragments,  named  fragments  "A"  through  "P", 
with  "A"  being  the  largest.  Open  reading  frames  within  each 
fragment  are  numbered  from  "left  to  right".  Finally,  each  open 
reading  frame  is  given  an  "R"  or  "L"  to  indicate  the  direction  of 
transcription  relative  to  the  "left"  end  of  the  fragment.  For 
example,  the  open  reading  frame  F13L  is  encoded  by  the  sixth-
largest  fragment  (F).  It  is  the  thirteenth  open  reading  frame  from 
the  left  end  of  the  fragment  and  is  transcribed  toward  the  left  end 
of  the  frag ment. 
Host  protein  synthesis  is  rapidly  and  efficiently  inhibited 
upon  infection  so  that  nearly  the  entire  translational  capacity  of  a 
cell  is  harnessed  by  the  virus.  Following  intermediate  gene 
expression  and  genome  replication  the  late  class  of  genes  are 
expressed.  The  majority  of  the  late  gene  products  are  involved  in 
the  late  stages  of  virion  development  serving  as  structural 
components  or  scaffolding  for  nascent  virions.  Virion 
morphogenesis  occurs  in  perinuclear  macromolecular  clusters 
containing  numerous  copies  of  the  viral  genome  and  virus  encoded 
proteins  referred  to  as  virus  factories,  viroplasm  or  virosomes. 
Immature  virions  form  by  packaging  viroplasm  within  membrane 
crescents  most  likely  derived  from  the  membranes  of  the 
intermediate  compartment (93)  but  possibly  produced  de  novo by 
virus-specific  membrane  forming  machinery  (41).  The  genome  is 
packaged  within  these  membrane  crescents  in  the  proteinaceous 4 
core with the virus-encoded RNA  polymerase and  numerous 
cofactors involved in the early stages of the virus life cycle. 
Concomitant with the proteolytic processing of the three major 
core proteins (104), the core condenses,  producing the first 
infectious form of the virus, which is  referred to as  intracellular 
mature virus (IMV). At this stage the core is  wrapped with one 
proteolipid envelope. 
.  .  .  .  ....  ~ 
. '" .. Of>  •  •  •  • 
Figure  1.1. The VV replication cycle. A diagram of the infected 
cell is  shown with an  exaggerated view of the endoplasmic 
reticulum (ER),  cis, medial, trans Golgi and the trans-Golgi 
network (C,  M,  T,  and TGN  respectively). The major stages of the 
virus life cycle are listed. Following late gene expression, 
previrion forms assemble to form intracellular mature virus 
(IMV). The IMV  is  targeted to the TGN  and following envelopment, 
intracellular enveloped virus (lEV) is  formed. lEV are propelled to 
the cell surface by the polymerization of actin filaments. Once 
released the virus may remain attached to the membrane as  cell-
associated enveloped virus (CEV)  or be  released into the medium 
as  extracellular enveloped virus (EEV). 5 
The  IMV  particle  is  targeted  to  the  trans-Golgi  network 
(TGN)  and  by  budding  through  the  compartment  acquires  two 
additional  membranes  (38).  After  envelopment  by  TGN  membranes, 
the  triple  membrane-bound  particle  referred  to  as  intracellular 
enveloped  virus  (lEV)  is  propelled  to  the  cell  surface  by  the 
formation  of  thick  actin  filaments  behind  it  (17).  At  the  cell 
surface  the  outermost  virion  membrane  may  be  lost  by  fusion  with 
the  cell  membrane,  resulting  in  the  release  of  a  double  membrane-
bound  particle  referred  to  as  extracellular  enveloped  virus  (EEV). 
If  the  virion  remains  attached  or  reattaches  to  the  cell  surface,  it 
is  referred  to  as  cell-associated  enveloped  virus  (CEV).  Some 
poxviruses  also  package  virions  in  cytoplasmic  inclusion  bodies 
referred  to  as  A-type  inclusions  (ATI),  which  are  primarily 
composed  of  a  single  protein,  the  ATI  protein  (63).  The  ATI  protein 
is  truncated  and  correspondingly  nonfunctional  in  VV  so  that  no 
inclusion  bodies  form  although  the  truncated  form  of  the  ATI 
protein  is  still  expressed  at  high  levels  (19). 
The  enveloped forms  of the  virus  (lEV,  EEV,  and  CEV)  are 
antigenically  distinct  from  the  IMV  particle  in  that  they  contain 
at  least  six  proteins  in  their  outer  envelope(s)  that  are  not 
present on  IMV.  They are  encoded  by  the  A33R  (81),  A34R  (23), 
A36R  (62),  A56R  (68),  85R  (25,  45)  and  F13L  (40)  open  reading 
frames  (ORFs)  of  VV.  All  of  these  proteins  have  been  demonstrated 
to  play  important  roles  in  the  formation,  release  and/or 
infectivity  of  EEV  with  the  exception  of  the  A56R  gene,  which 
encodes  the  viral  hemagglutinin.  None  of  these  proteins  affects 
the  formation  of  IMV.  Preliminary  studies  suggest  that  the  IMV 
particle  also  contains  proteins  not  found  on  the  multiply 
enveloped  forms  of  the  virus.  The  ATI  protein  and  the  4c  protein 
are  unique  to  IMV  and  although  their  biological  relevance  is  not 
known  they  may  represent  an  evolutionary  relic.  While  VV  does  not 
occlude  virions  in  ATls,  the  closely  related  cowpox  virus  does 
(63).  In  that  system,  it  has  been  demonstrated  that  the  4c  protein 
is  required  for  occlusion 'of virions  in  ATls.  It  may  be  that  the 6 
association  of the  ATI  and  4c  proteins  with  the  VV  IMV  particle  is 
an  abortive  attempt  at ATI  formation. 
The  virus  and  its  life  cycle  are  complex  and  not  completely 
understood.  Throughout  its  life  cycle  the  virus  uses  numerous 
cellular  protein  processing  pathways  to  include  proteolytic 
processing,  phosphorylation,  sulfation,  glycosylation,  and  ADP-
ribosylation  (103).  Here  we  review  the  acylation  of  VV  proteins 
and  discuss  the  significance  of  these  proteins  and  their 
respective  acyl  modifications  in  the  biology  of  VV. 
1.1 .2  Overview  of  Protein  Acylation 
Two  classes  of  fatty  acylated  proteins  exist  in  eukaryotic 
cells  (53)  and  by  extension  are  present  in  VV-infected  cells  as 
well.  Labeling  cultured  cells  with  [3H]-myristic  acid  ([3H]-MA)  or 
[3H]-palmitic  acid  ([3H]-PA),  identifies  distinct  subsets  of 
proteins.  The  distinction  between  the  two  classes  can  be 
determined  in  two  ways.  First,  myristylation  of  proteins  is  a  co-
translational  event  and  is  inhibited  by  the  addition  of  reagents 
which  block  translation.  Under  these  conditions,  palmitylation  of 
previously  translated  proteins  occurs  normally  while 
myristylation  does  not.  Second,  the  palmitate-protein  bond  is 
labile  in  the  presence  of  mild  alkali  or  neutral  hydroxylamine  due 
to  the  thioester  linkage  while  the  amide-linked  myristate  is 
stable  under  the  same  conditions.  Many  palmitylproteins  are 
membrane  associated  either  directly  through  the  palmitate  moiety 
or  as  transmembrane  proteins  anchored  by  the  fatty  acid,  although 
a  few  are  secreted  from  cells.  Cell-associated  palmitylproteins 
are  distributed  throughout  the  cell,  with  the  greatest 
concentration  at  the  cell  surface.  Myristylproteins,  on  the  other 
hand,  may  be  cytoplasmic  or  membrane-associated.  Some  proteins 
are  modified  by  both  myristic  and  palmitic  acids,  with  both  acyl 
moieties  contributing  to  protein  function  and  localization. 7 
Myristylation  of  proteins  involves  the  transfer  of  myristate 
from  myristyl-Coenzyme  A  to  the  amino-terminal  motif 
MGXXX(S/TIAIC/N)  (using  the  single-letter  amino  acid  code)  of 
proteins  by  the  enzyme  N-myristoyl  transferase  (NMT)  (100)  This 
motif  bestows  substrate  specificity  for  the  Saccharomyces 
cerevisiae-encoded  enzyme,  and  although  the  human  homologue 
has  similar  specificity,  it  may  not  be  entirely  the  same.  The 
initiating  methionine  is  removed  by  methionine  aminopeptidase 
during  translation  and  NMT  recognizes  the  newly  generated  amino-
terminal  glycine  of  the  nascent  peptide  after  approximately 
twenty  residues  are  free  of  the  ribosome.  NMT  transfers 
myristate  to  the  glycine  residue,  after  which  the  enzyme  releases 
the  peptide  and  translation  continues  normally.  Mutations  that 
change  any  of  the  conserved  residues  of  the  motif  inhibit 
myristylation,  with  the  greatest  inhibition  achieved  by  replacing 
the  penultimate  glycine  with  any  residue  (101).  The  residues  at 
position  six  of  the  motif  are  less  important,  with  low  levels  of 
myristylation  occurring  even  if they  are  changed.  It  should  be 
noted,  though,  that  not  all  proteins  containing  the  amino-terminal 
motif  are  myristylated,  indicating  that  there  are  additional 
requirements.  See  Figure  1.2  for  the  "ball  and  stick"  model  of a 
multiply  fatty  acylated  peptide. 
Recently,  myristylation  has  been  demonstrated  to  occur  on 
internal  residues  of  proteins  (95).  Although  the  motif  directing 
this  modification  has  not  been  discovered,  the  myristate  acceptor 
residues  appear to  be  arginine  or  lysine  (Figure  1.2).  This  may  be 
due  to  the  presence  of  free  amines  in  their  side-chains  and  is 
supported  by  experiments  demonstrating  their  insensitivity  to 
neutral  hydroxylamine,  suggesting  amide  linkage  for  this 
modification  as  well.  The  enzyme(s)  responsible  for  internal 
myristylation  is  (are)  unknown. 
Palmitylation  of  proteins  remains  an  enigma  for 
researchers.  Palmitylproteins  are  more  aptly  described  as  ester-
type  fatty  acylated  (86)  proteins  or  even  S-acylated  proteins  (73), 8 
in  reference to the sulfur atom in the  side-chain of the acceptor 
cysteine. Some proteins are preferably modified by stearic or 
oleic acids over palmitic acid, but for the most part palmitate is 
the predominant fatty acid on these proteins with small 
percentages of them being modified by stearate and oleate or even 
arachidonate (87). While cysteine is the most common acceptor 
residue, serine or threonine may also serve as  palmitate 
acceptors (8), so even the description of these proteins as  S-
acylated is  not totally accurate. 
(asparagine) 
(cysteine) 
(threonine) 
myristate 
methionine 
~ 
palmitate 
(alanine)  (arginine) 
(any)  lysine 
5  ? 
myristate 
Figure  1.2. Structure of a hypothetical acylated peptide. A peptide 
consisting of the canonical amino-terminal myristylation motif is 
shown. The amino-terminal methionine is  cleaved and  the 
penultimate glycine residue is  modified by the amide-bound 14-
carbon fatty acid myristate. Cysteine in  position 3 is  modified by 
the thioester-linked 1  6-carbon fatty acid palmitate as  in Type 4 
palmitylproteins (see text). An  internal lysine residue is  modified 
by myristate as  well. Alternate acceptable amino acids for each 
position are indicated in  parentheses above the peptide backbone. 9 
To  date,  a  consensus  motif  directing  palmitylation  of 
proteins  as  well  as  the  enzyme(s)  responsible  for  the 
modification  is  (are)  unknown.  Palmitylprotein  acyltransferase 
has  been  described  as  a  membrane-bound  component  of cells,  with 
in  vitro  activity  detected  in  endoplasmic  reticulum,  Golgi  and 
plasma  membrane  fractions  of cells  (4).  The  enzyme  has  a 
requirement  for  the  activated  form  of  palmitate,  palmityl-
coenzyme  A,  but  little  else  is  known  about  it.  An  enzyme  capable 
of  removing  palmitate  from  proteins,  palmityl-protein 
thioesterase,  has  been  discovered  (14,  22,  106),  and  is  defective 
in  infantile  neuronal  ceroid  lipofuscinosis. 
Some  general  characteristics  of  palmitylproteins  are  known 
and  have  allowed  us  to  classify  them  into  four  subclasses  (74). 
Type  I  palmitylproteins  are  transmembrane  proteins  that  are 
modified  on  cysteines  at  or  near  the  cytoplasmic  membrane  face. 
This  group  is  typified  by  the  G-protein  coupled  receptors  and 
includes  the  vesicular  stomatitis  virus  G  and  the  influenza  virus 
hemagglutinin  proteins.  The  palmitylation  of  Type  II  proteins 
occurs  in  the  carboxy-terminal  region  and  is  dependent  on  prior 
prenylation  of  cysteine  in  the  CAAX  motif  at  the  extreme  carboxy-
terminus.  Members  of  this  group  include  the  ras  proteins.  Types  III 
and  IV  are  dually  fatty  acylated  in  the  amino-terminal  region. 
Both  groups  are  myristylated  on  glycine  of  the  motif 
MGXXX(S/T/AlC/N).  Type  III  palmitylproteins  are  modified  on  one 
or  more  cysteines  within  the  first  10 to  20  amino  acids  while 
Type  IV  palmitylproteins  are  modified  on  cysteine  immediately 
following  the  myristylated  glycine  residue  (Figure  1.2).  Efficient 
palmitylation  of  Types  III  and  IV  is  dependent  on  prior 
myristylation.  The  alpha  subunits  of  the  heterotrimeric  G-
proteins  are  grouped  as  Type  III  or  IV. 10 
1.2  Identification  of  VV  Acylproteins 
Since  the  discovery  that  VV  encoded  a  palmitylated  protein 
localized  to  the  TGN  in  infected  cells  and  present  on  the  surface 
of  virions  (38),  a  great  deal  of  work  has  been  performed  to 
discover  other  VV  acylproteins,  their  role  in  the  VV  life  cycle  and 
the  significance  of  the  modification.  Workers  in  our  laboratory 
have  confirmed  the  existence  of  at  least  6  myristylproteins  (27) 
and  8  palmitylproteins  (16)  encoded  by  VV.  Their  salient  features 
are  summarized  in  the  Vaccinia  Acylprotein  table. 
1.2.1  Identification  of  VV  Myristylproteins 
The  discovery  of  the  myristylation  motif  allowed  workers  in 
our  lab  to  undertake  a  systematic  approach  to  identify  VV-
encoded  myristylproteins.  The  entire  sequence  of  the  Copenhagen 
strain  of  VV  is  known  (32),  and  by  deduction,  the  amino  acid 
sequences  of  the  proteins  it  encodes.  Four  of  the  potential  peptide 
seque"nces  contain  the  amino-terminal  motif  MGXXX(S/T/A/C/N). 
They are encoded by the  A16L,  E7R,  G9R and  L  1  R ORFs,  producing 
proteins  with  predicted  masses  of  43.6,  19.5,  38.8  and  25  kDa 
respectively.  Labeling  VV-infected  cells  with  [3H]-MA  and  " 
resolution  by  SDS-PAGE  demonstrates  that  six  polypeptides 
incorporate  the  label  with  electrophoretic  mobilities  indicating 
masses  of  92,  39,  36,  25,  17,  and  14  kDa.  By  in  vitro  transcription 
and  translation,  the  identities  of  the  39-,  36-,  25-,  and  17-kDa 
proteins were  demonstrated  to  be  encoded  by  the  A  16L,  G9R,  L  1  R 
and  E7R  ORFs  respectively,  as  predicted  (29,  57).  In  this  system, 
the  ORFs  were  cloned  into  plasmid  vectors  downstream  of  T7 
promoters.  By  transcription  using  T7  RNA  polymerase  and 
translation  in  the  presence  of  [3H]-MA  using  wheat  germ  extracts 
the  proteins  were  demonstrated  to  incorporate  the  label.  Mutants 
of  these  proteins,  in  which  the  penultimate  glycine  was  changed 1 1  
Vaccinia  Acylproteins. 
Protein/Gene  Modification  Site  of Modification  Localization  Ref. 
15K/A14L  myristate  unknown  ERGICc, IMvd  (77) 
envelope 
unnameda/A16L  myristate  MG*XXX(S/T/A/C/N)b  cytosol  (57) 
ATI  myristate  unknown  cytosol,  IMV  (56) 
protein/A25L  palmitate  unknown 
unnamedlA33R  palmitate  unknown  TGNe,IEvt,  (81 ) 
CEVJ,EEvh 
outer envelope 
gp42/B5R  palmitate  unknown  TGN, lEV, CEV,  (25,  45) 
EEVouter 
envelope, 
plasma 
membrane 
unnamedlE7R  myristate  MG*XXX(S/T/A/C/N) 	 cytosol  (57) 
p37/F13L  palmitate  cysteine  185  TGN, lEV, CEV,  (40) 
cysteine  186  EEVouter 
envelope 
unnamedlG9R  myristate  MG*XXX(S/T/A/C/N) 	 unknown  (57) 
M25/L1 R  myristate  MG*XXX(S/T/A/C/N) 	 IMV envelope  (71) 
p14/unknown  palmitate  unknown 	 virion  ( 1 6) 
associated 
p17/unknown  palmitate  unknown 	 virion  ( 1 6) 
associated 
a Unnamed  VV  proteins  are  referred  to  by  open  reading  frame  in 
the  text.,  b amino-terminal  myristylation  motif.  *  indicates  the 
myristyl  acceptor  glycine  residue  after  cleavage  of  the  initiating 
methionine.,  c endoplasmic  reticulum-Golgi  intermediate 
compartment,  d  intracellular  mature  virus,  e trans-Golgi  network, 
f intracellular  enveloped  virus,  g cell-associated  enveloped  virus, 
h extracellular  enveloped  virus 12 
to  alanine,  did  not  incorporate  label  in  this  system.  Antibodies 
directed  against  these  proteins  immunoprecipitated  [3H]-MA 
labeled  proteins  from  infected  cells  that  co-migrated  with  the  in 
vitro  translated  proteins  as  well  as  proteins  from  whole  cell 
extracts,  confirming  their  modification  by  myristate  in  vivo  as 
well.  High-performance  liquid  chromatography  (HPLC)  of  fatty 
acids  extracted  from  these  proteins  demonstrated  that  myristate 
was  the  predominant  modifying  moiety  but  palmitate  was  also 
present.  This  is  most  likely  the  result  of  interconversion  of  the 
myristate  post-modification,  as  the  addition  of  [3H]-PA  to 
infected  cells  did  not  label  these  same  proteins  efficiently. 
The  identity  of  the  92-kDa  myristylprotein  was  deduced  by 
Martin  et a/ (56).  Although  a  number  of  VV-encoded  proteins  are 
known  to  migrate  with  similar  electrophoretic  mobility,  only  one 
matched  the  observed  expression  kinetics.  Pulse-chase  labeling  of 
infected  cells  with  [3H]-MA  demonstrated  that  the  label  was 
incorporated  most  efficiently  at  very  late  times  post-infection. 
The  only  protein  known  to  be  expressed  by  VV  in  this  manner was 
the  ATI  protein.  To  confirm  that  the  ATI  protein  was  indeed 
myristylated,  cells  were  infected  with  the  Western  Reserve  (WR) 
or  Copenhagen  (COP)  strains  of VV  or the  closely  related  cowpox 
virus  and  cultured  in  the  presence  of  [3H]-MA.  Cowpox  is  known  to 
encode  the  full-length  (160  kDa)  ATI  protein  while  WR  encodes  a 
truncated 92  kDa  form.  COP  does  not encode  the  ATI  protein  due  to 
a  frameshift  mutation  that  introduces  a  stop  codon  near  the 
initiating  methionine.  Resolution  of  the  labeled,  infected  cell 
extracts  by SDS-PAGE demonstrated  that COP  did  not encode  a 
high  molecular  weight  myristylprotein  while  cowpox  and  WR 
encoded  160-kDa  and  92-kDa  myristylproteins  respectively. 
Confirmation  of  these  findings  was  obtained  by  the  development 
of  antiserum  to  the  ATI  protein  that  was  used  to 
immunoprecipitate  the  [3H]-MA  labeled  protein  from  infected  cell 
extracts. 13 
The  ATI  protein  does  not  contain  the  amino-terminal 
myristylation  consensus  motif,  suggesting  that  the  modification 
occurred  either  at  an  internal  site  or  that  the  label  was 
incorporated  as  result  of  interconversion  of  myristate  to 
palmitate.  It  turns  out  that  both  scenarios  are  probably  correct. 
HPLC  analysis  of  fatty  acids  extracted  from  the  ATI  protein 
confirmed  that  myristate  and  palmitate  were  both  present  on  the 
protein,  a  finding  that  is  not  uncommon  for  myristylproteins.  It 
was  also  found  that  translational  inhibitors  reduced  the 
efficiency  of  label  incorporation  but  did  not  block  it  entirely, 
suggesting  that  the  protein  was  palmitylated,  while  at  the  same 
time,  treatment  with  neutral  hydroxylamine  did  not  entirely 
remove  the  label,  suggesting  stable  amide  linkage  for  the  fatty 
acid.  Addition  of  [3H]-PA  to  infected  cell  cultures  also  resulted  in 
label  incorporation  by  the  ATI  protein.  Evidence  presented  in 
Chapter  2  is  contradictory  to  these  findings  though.  It  may  be  that 
the  92-kDa  palmitylprotein  is  in  fact  a  distinct  but  co-migrating 
protein. 
No  VV-encoded  protein  is  predicted  to  match  the  size  of  the 
14-kDa  myristylprotein  and  contain  the  amino-terminal 
myristylation  motif,  suggesting  that  this  protein  represents  the 
second  example  of  an  internally  myristylated  VV  protein.  In  a 
report  by  Rodriguez  et a/ (77)  this  protein  was  identified  as  being 
encoded  by  the  A  14L ORF.  In  arriving  at  this  conclusion,  the 
authors  labeled  infected  cells  with  [3H]-MA  and 
immunoprecipitated  the  A  14L  protein  (which  migrated  as  a  15-
kDa  protein  in  their  system),  demonstrating  that  it  incorporated 
label.  They  did  not,  however,  demonstrate  that  the  label  was 
incorporated  as  myristate  and  not  some  other  long  chain  fatty 
acid  arising  from  interconversion.  In  addition,  they  suggested  a 
number  of  internal  glycine  residues  as  possible  sites  of 
modification.  This  is  not  likely  to  be  the  case  as  glycines  do  not 
have  free  amino  groups  to  react  with  the  carboxyl  moiety  of  the 
fatty  acid.  It  is  more  likely  that  the  protein  is  modified  by 
myristate  on  Iysine(s)  or  arginine(s)  (which  have  free  amines)  at 14 
internal  sites  or  that  the  fatty  acid  was  converted  to  palmitate  or 
other  long-chain  fatty  acid  and  added  through  an  ester-type 
linkage  to  cysteine,  serine  or  threonine.  Further  analysis  of  this 
protein  needs  to  be  performed  to  confirm  that  it  is  truly 
myristylated  and  to  define  the  exact  nature  of the  acyl 
modification. 
1.2.2  Identification  of  VV  Palmitylproteins 
The  first  report  of  a  VV-encoded  fatty  acylprotein  was  by 
Hiller  et al (38).  They  described  a  37-kOa  palmitylated  protein 
(p37)  present  in  Golgi  membrane  fractions  of  infected  cells  and  in 
the  outer  envelope  of  EEV.  Since  this  initial  finding  the  protein 
has  been  confirmed  to  be  the  product of the  F13L  ORF  in  numerous 
reports  (9,  40,  65).  Additionally,  Child  and  Hruby  have 
demonstrated  the  existence  of  at  least  five  more  palmitylproteins 
induced  by  VV  (16).  By  addition  of  [3H]-PA  to  infected  cells  and 
SOS-PAGE  resolution  of  the  labeled  proteins,  they  confirmed  that 
VV  encodes  proteins  that  incorporate  the  label  with 
electrophoretic  mobilities  of  92,  42,  37,  26,  17,  and  14  kDa.  To 
date,  no  laboratory  has  undertaken  a  directed  effort  to  identify 
these  proteins  although  the  identities  of  some  have  been  obtained 
as  an  aside  in  other  efforts  to  characterize  VV  proteins. 
Isaacs  et a/ (45) confirmed  that  addition  of  [3H]-PA  to  VV-
infected  cells  resulted  in  the  specific  labeling  of  a  42-kDa 
glycoprotein  (gp42).  Antibodies  known  to  react  with  the  product 
of  the  B5R  ORF  immunoprecipitated  gp42,  confirming  its  identity. 
It  most  likely  is  a  member  of  the  Type  1  palmitylprotein  subclass. 
Following  cleavage  of  the  signal  sequence  the  protein  is  oriented 
in  the  membrane  as  a type  I transmembrane  protein,  spanning  it 
only  once,  and  having  a  very  short  carboxy-terminal  tail  exposed 
to  the  cytoplasm.  The  protein  transits  the  cell  using  the  normal 
protein  export  pathway,  acquiring  glycosyl  moieties  in  the 15 
process,  and  eventually  resides  in  the  TGN  and  plasma  membranes. 
The  palmitate  modification  site  is  unknown  although  it  is  likely 
that  it  is  in  the  carboxy-terminal  cytoplasmic  tail,  that  contains 
a  number  of  cysteine  residues. 
The  26-kDa  palmitylprotein  that  we  identified  actually 
migrates  as  four  distinct  species  in  reducing  SDS-PAGE  gels;  as  a 
55  kDa  species  and  as  3 species  of 23  to  28  kDa.  Glycosylation 
inhibitors  block  the  appearance  of  the  three  slower  migrating 
species,  suggesting  a  complex  glycosylation  pattern.  This  protein 
was  once  thought to  be  the  product of the  A34R  ORF  (84)  but  has 
since  been  demonstrated to  be  encoded  by  the  A33R  ORF (81).  The 
misidentification  is  an  understandable  one.  When  the  protein  was 
first  identified  as  the  product  of  the  A34R  ORF,  it  was  known  that 
the  A34R  protein  (gp22)  was  a  glycoprotein  migrating  in  SDS-
PAGE  gels  with  electrophoretic  mobilities  of  22  to  24  kDa  and 
was  unique  to  the  outer envelope  of  EEV  (23).  By  using  a 
monoclonal  antibody  generated  to  EEV-specific  proteins,  a 
palmitylprotein  exhibiting  similar  characteristics  was 
immunoprecipitated  from  [3H]-PA-labeled  infected  cell  extracts. 
It  has  since  been  determined  that  the  monoclonal  antibody  used  is 
specific  for  the  product  of  the  A33R  ORF.  The  A33R  protein 
(referred  to  as  gp23-28)  is  predicted  to  be  a  type  II 
transmembrane  protein  with  a  short  amino-terminal  cytoplasmic 
tail.  Based  on  this  prediction,  the  A33R  protein  is  most  likely  a 
member  of  the  Type  I  palmitylprotein  subclass. 
Since  the  initial  discovery  that  p37  was  encoded  by  the  F13L 
ORF,  we  have  made  a  systematic  effort  to  identify  the  site  of 
modification  and  understand  the  significance  of  the  acyl  moiety  in 
the  biology  of  VV.  Although  the  primary  amino  acid  sequence 
necessary  for  recognition  by  palmitylprotein  acyltransferase  and 
subsequent  transfer  of  palmitate  to  proteins  is  not  known, 
Ponimaskin  and  Schmidt  have  identified  sequence  constraints  for 
numerous  viral  glycosylated  palmitylproteins  (69).  Their 
observations  indicate  that  transmembrane  proteins  containing 16 
cysteine  residues  from  within  six  amino  acids  into  the 
transmembrane  region  (on  the  cytoplasmic  side)  to  ten  amino 
acids  away  from  the  membrane:cytoplasm  boundary  are  efficient 
substrates  for  palmitylation.  Cysteines  located  in  the  middle  of 
the  membrane,  on  the  extracellular  face,  or  more  than  10  amino 
acids  away  from  the  membrane:cytoplasm  boundary,  are  not 
efficiently  palmitylated.  Cysteines  alone,  near  the  membrane,  are 
not  sufficient  to  direct  palmitylation.  Insertion  of  cysteine 
residues  at  the  membrane  boundary  of  nonpalmitylated  proteins 
did  not  convert  them  to  substrates  for  palmitylation. 
It  was  once  thought  that  p37  was  a  transmembrane  protein, 
as  it  is  known  to  be  membrane-associated  within  infected  cells, 
fractionates  with  membrane-bound  components  of  cells  and  is 
associated  with  the  EEV  envelope.  In  fact,  the  membrane 
association  is  peripheral  in  nature  and  interestingly  is  mediated 
by  the  palmityl  moiety  alone  (34,  91).  Treatment  of  p37-
containing  membrane  fractions  of  cells  with  neutral 
hydroxylamine  results  in  the  release  of  p37  from  the  membrane, 
leaving  it  free-floating  in  the  aqueous  fraction.  Type  III  and  IV 
palmitylproteins  are  peripherally  associated  with  membranes  but 
are  also  substrates  for  myristylation.  p37  is  not  myristylated  so 
it  cannot  be  classified  as  Type  III  or  IV.  It  may  be  appropriate  to 
suggest  that  p37  is  a  member  of  a  novel  subclass  of 
palmitylproteins  - one  in  which  palmitylation  is  necessary  and 
sufficient  for  peripheral  membrane  association. 
In  our  analysis  of  the  primary  amino  acid  sequence  of  p37, 
using  the  guidelines  of  Ponimaskin  and  Schmidt,  we  were  unable 
to  predict  potential  modification  sites  in  the  protein.  Therefore, 
we  analyzed,  by  sequence  alignment,  numerous  palmitylproteins 
whose  sites  of  modification  were  known,  and  we  discovered  a 
loosely  conserved  motif.  We  found  that  cysteine  (or  a  cysteine 
doublet)  within  a  transmembrane  or  hydrophobic  stretch  of  amino 
acids  that  was  preceded  by  two  aliphatic  residues  and  followed  by 
another  served  as  a  substrate  for  palmitylation.  Comparison  of 17 
this  motif  to  the  p37  sequence  yielded  one  possible  site  for 
modification  - a  cysteine  doublet  in  the  middle  of  a  hydrophobic 
domain  in  the  central  region  of  the  protein.  Mutation  of one  or the 
other  of  these  cysteines  to  serine  reduced  the  efficiency  of 
palmitylation  while  mutation  of  both  to  serine  inhibited  it 
completely  (34). 
At  least  three  VV-encoded  palmitylproteins  are 
unidentified.  The  14-,  17-,  and  92-kDa  proteins,  observed  by  SDS-
PAGE  resolution  of  labeled,  infected  cell  extracts,  are  encoded  by 
unknown  ORFs.  In  addition  to  these  easily  detected  proteins,  there 
may  be  others  not  so  readily  observed. 
1.3  Biological  Significance  of  VV  Acylproteins 
1.3.1  Myristylproteins 
The  L  1  R protein  (also  referred  to  as  M2S)  is  the  best 
characterized  VV  myristylprotein  regarding  protein  function  and 
significance  of  the  myristyl  modification.  The  protein  is  localized 
to  the  envelope  of the  I  MV  particle  and  is  predicted  to  span  ~he 
membrane  twice  (71).  There,  it  presumably  acts  as  a  necessary 
structural  component  of  the  developing  virion  (see  Figure  1.3 for 
hypothetical  membrane  topologies  and  virion  association  of  all  VV 
acylproteins).  A  mutant  virus  in  which  transcription  of  the  L  1  R 
ORF  was  inhibited  by  the  lac  repressor  unless  isopropyl-thio-
galactopyranoside  (IPTG)  was  added  to  the  medium,  could  not 
progress  past  the  virion  morphogenetic  stage  at  which  the  core 
condenses  to  form  IMV  (72).  By  electron  microscopy,  numerous 
immature  virions  were  observed  as  membrane-enclosed  viroplasm. 
Analysis  of  the  virion  core  proteins  confirmed  that  proteolytic 
processing  to  their  mature  forms  did  not  occur  either, 18 
• 
Figure  1.3. Cellular and viral distribution of VV acylproteins. A 
close-up view of an  infected cell is shown, highlighting 
membranes and structures involved in  virion morphogenesis. 
Membrane crescents derived from the endoplasmic reticulum-
Golgi intermediate compartment (ERGIC)  form in  the vicinity of 
the virosome leading to the production of intracellular mature 
virus (IMV). IMV is enveloped by membranes from the trans-Golgi 
network (TGN)  forming intracellular enveloped virus (lEV). 
Following fusion of the outermost lEV envelope with the plasma 
membrane, extracellular enveloped virus (EEV)  is  released into the ' 
extracellular environment. Hypothetical protein:membrane 
interactions are shown. The amino- and carboxy-terminal ends of 
the proteins are indicated by "N" and  "C" respectively. Myristyl and 
palmityl modifications are indicated by "M" and  "P" respectively. 19 
demonstrating  the  co-dependency  of  both  processes.  This  virus 
could  be  rescued  by  addition  of  I  PTG  or  by  transient  expression  of 
the  wild-type  L  1  R  from  a  transfected  plasmid  carrying  the  gene. 
Transfection  with  a  plasmid  encoding  a  mutant  L  1  R,  in  which  the 
myristyl  acceptor  glycine  had  been  changed  to  alanine,  could  not 
rescue  the  virus.  It  is  clear  from  these  findings  that  L  1  R  plays  a 
significant  role  in  the  maturation  of  virions.  Additionally,  the 
myristylation  of  L  1  R  appears  to  be  essential  for  protein  function. 
Although  the  myristylation  of  L  1  R  may  assist  in  the  correct 
folding  of  the  protein,  it  is  also  involved  in  targeting  the  protein 
to  virion  membranes.  A  fusion  protein,  in  which  the  first  twelve 
amino  acids  from  L  1  R were  fused  to  the  entire  bacterial 
chloramphenicol  acetyl  transferase  gene,  was  myristylated  and 
present  in  virions  (70).  The  molecular  mechanisms  by  which  L  1  R 
functions  are  unknown. 
Although  the  ATI  protein  is  known  to  function  as  a 
structural  matrix  for  the  formation  of  ATI  bodies  in  other 
poxviruses  (63),  it  has  no  demonstrable  function  in  VV  (1).  As 
stated  above,  VV  expresses  a  truncated  form  of the  protein  that  is 
conserved  across  numerous  strains  with  the  exception  of  the  COP 
strain,  which  does  not  express  the  ATI  protein.  There  has  been 
some  speculation  that  it  may  serve  as  an  immune  decoy  or 
deterrent  to  phagocytosis  but  there  are  no  supporting  data  for  this 
hypothesis  (19).  Our  analysis  of  the  significance  of  the  acyl 
modifications  has  been  hindered  by  the  lack  of  an  observable 
phenotype  attributable  to  this  protein.  Likewise,  the  large  size  of 
the  protein  has  made  mutational  analysis  of  the  protein  a  lengthy 
task. 
The  1S-kDa  myristylprotein  product  of  the  A  14L  ORF  has 
been  demonstrated  to  be  associated  with  membranes  of  the 
endoplasmic  reticulum-Golgi  intermediate  compartment  (77).  In 
addition  to  acylation,  the  protein  is  phosphorylated.  The  functions 
of  both  modifications  is  unknown.  The  protein  has  two  hydrophobic 
domains  predicted  to  be  alpha-helical  in  structure,  characteristic 20 
of  transmembrane  proteins.  The  protein  exists  as  part  of  a 
complex  with  the  A  17L  (21  kDa)  and  the  A27L  (14  kDa)  proteins 
with  unknown  stoichiometry  (77).  These  proteins  collectively  are 
involved  in  the  formation  of  previrion  membrane  crescents  at  the 
site  of  virion  development  and  are  found  associated  with  the  outer 
envelope  of  immature  virions  and  IMV.  They  presumably  comprise 
a component of the  inner membranes  of lEV,  CEV  and  EEV.  It has 
been  recently  reported  that  both  the  A  14L and  A  17L gene  products 
are  necessary  for  the  recruitment  of  intermediate  compartment 
membranes  to  virus  factories  (78). 
The  functions  of  these  three  remaining  myristylproteins 
have  not  yet  been  determined.  Hydropathy  and  secondary  structural 
predictions  suggest  that  the  A16L  and  G9R  proteins  might  be 
targeted  to  membranes  while  the  E7R  protein  is  largely 
hydrophilic  (57).  Surprisingly,  subcellular  fractionation  of 
infected  cells  into  soluble  and  particulate  fractions  demonstrated 
that the  A  16L and  E7R  proteins  were  soluble.  The  G9R  protein  was 
not  detected  in  this  assay,  suggesting  that  it  is  made  in  low 
quantity,  or  that  it  is  labile  and  was  degraded  in  the  purification 
process.  Neither  of  these  three  proteins  was  detected  in  purified 
virions. 
1.3.2  Palmitylproteins 
The  three  VV  palmitylproteins  that  have  been  identified  all 
prove  essential  to  the  formation  of  lEV,  virion  egress  and  release 
of  EEV/CEV  from  cells.  This  process  has  been  the  subject  of 
intense  scrutiny  by  numerous  laboratories,  all  providing  pieces  to 
the  puzzle.  The  IMV  particle,  while  fully  infectious  and 
representing  the  majority  of  virus  purified  from  tissue  culture 
systems,  most  likely  is  an  intermediate  virion  in  vivo.  IMV  are 
targeted  to  the  TGN  and  by  budding  through  it  acquire  additional 
membranes,  forming  lEV  (38).  The  formation  of  lEV  is  dependent 21 
on  expression  of the  A27L  gene  encoding  the  14-kDa  protein  found 
on  the  surface  of  IMV  (75),  as  well  as  the  products  of the  A33R 
(gp23-2S)  (SO),  A36R  (gp45-50)  (62),  B5R  (gp42)  (26,  45)  and 
F13L  (p37)  (9)  genes,  all  specific  for  the  multiply  enveloped 
forms  of  virions.  By  a  poorly  understood  mechanism,  lEV  are  able 
to  recruit  actin,  forming  thick  filaments  that  propel  the  virus 
unidirectionally  to  the  cell  surface,  sometimes  into  neighboring 
uninfected  cells  (17).  An  additional  requirement  for  this  task  is 
the  A34R  gene  product,  gp22  (110),  which  is  also  a component  of 
lEV,  CEV  and  EEV  outer  membranes.  Deleting  or  inhibiting  the 
expression  of  any  of  these  genes  results  in  the  accumulation  of 
IMV  and/or  inhibition  of  virus  dissemination.  The  exact  role  each 
of  these  proteins  plays  is  not  clear. 
Recent  data  suggest that p37  is  a member  of  the 
phospholipase  D superfamily  based  on  conserved  sequences  (15, 
97).  Although  no  phospholipase  D activity  could  be  detected  in  VV-
infected  cell  extracts,  the  purified  protein  was  demonstrated  to 
possess  phospholipase  A  and  C activity  (2).  Mutation  of the 
sequences  in  p37  that  are  conserved  in  the  phospholipase  family 
of  proteins  resulted  in  a  protein  that  was  no  longer  capable  of 
functioning  regarding  IMV  envelopment,  suggesting  that 
phospholipase  activity  is  a  necessary  protein  function. 
Palmitylation  of  p37  is  also  necessary  for  function  (34).  In  this 
thesis  we  have  demonstrated  that  p37  is  palmitylated  on  both 
cysteines  of  a  doublet  in  the  central  region  of  the  protein.  A 
mutant  virus  expressing  a  nonpalmitylated  form  of  p37  was 
defective  for  envelopment  of  IMV  and  subsequent  release  of  virus 
from  the  cell.  Wild-type  p37  is  normally  a  component  of  TGN 
membranes  but  the  nonpalmitylated  p37  was  soluble  in  the 
cytoplasm  of  infected  cells.  It  would  appear  that  VV  requires  the 
very  specifically  localized  phospholipase  activity  of  p37  to 
progress  past  the  IMV  morphogenetic  stage.  The  substrates  of  this 
enzyme  are  unknown. 22 
The  42-kDa  glycosylated  palmitylprotein,  gp42,  is  a  type  1 
transmembrane  protein  present  on  the  surface  of  infected  cells 
and  on  the  outer envelopes of lEV,  CEV  and  EEV  (65).  A large 
amino-terminal  region  of  the  protein  is  exposed  to  the 
extracellular  environment  and  contains  4  short  consensus  repeats 
characteristic  of  complement  control  factors.  VV  encodes  a 
secreted  homologue  of  gp42  that  has  been  demonstrated  to  bind 
complement  (44),  but  whether  gp42  functions  in  an  analogous 
manner  is  not  known.  Deletion  mutants  of the  85R  ORF 
demonstrate  the  significance  of  this  protein  in  the  VV  life  cycle. 
Viruses  that  do  not  make  gp42  are  attenuated  in  vivo  and  form 
small  plaques  in  tissue  culture  (109).  This  is  a  direct  result  of 
the  inability  of  these  viruses  to  produce  normal  amounts  of  EEV 
and  not  related  to  the  loss  of  the  extracellular  short  consensus 
repeats.  Restoration  of  the  transmembrane  domain  and  short 
carboxy-terminal  cytoplasmic  tail  rescues  B5R  deletion  viruses, 
suggesting  that  the  extracellular  domain  is  dispensable  for  the 
formation  of  EEV  (49).  Not  only  is  the  carboxy-terminal  region  all 
that  is  necessary  for  protein  function,  it  is  also  sufficient  to 
target  heterologous  fusion  proteins  to  EEV  particles  (49).  This 
does  not  preclude  the  possibility  of  a  role  for  the  extracellular 
domain  though.  Based  on  our  predictions,  the  carboxy-terminus  of 
gp42  is  also  the  site  of  palmitate  modification.  The  significance 
of  the  modification  is  unknown,  but  considering  the  importance  of 
this  region  it  will  be  of  interest  to  investigate  it. 
The  A33R  protein,  also  referred  to  as  gp23-28,  is  targeted 
to  the  membranes  of the  TGN  and  is  predicted  to  be  oriented  as  a 
type  II  transmembrane  protein  with  the  amino-terminal  region 
exposed  to  the  cytoplasm  (81).  After  envelopment  of  IMV  by  TGN 
membranes,  the  protein  is  present  in  the  outer envelopes  of  lEV, 
CEV  and  EEV  and  is  required  for  their  formation  (80).  Deletion  of 
the  A33R  gene  results  in  a  small-plaque  phenotype,  indicating  a 
reduced  dissemination  efficiency.  The  exact  role  this  protein 
plays  is  unknown,  as  is  the  site  of  palmitate  modification. 23 
1.4  Discussion 
VV  is  a  large  virus  with  a  complex  life  cycle.  This 
complexity  is  due  to  more  than  200  gene  products  expressed  in 
VV-infected  cells.  To  maintain  regulatory  control  and  correct 
targeting,  the  virus  has  adopted  many  cellular  protein  processing 
pathways  for  its  own  use.  This  in  itself  highlights  the  advantages 
of  using  VV  as  a  transient  mammalian  expression  system. 
Proteins  expressed  in  VV-infected  cells  are  modified  in  their 
native  manner  and  are  targeted  intracellularly  or  transit  the  cell 
normally.  Protein  modifications  known  to  occur  in  VV-infected 
cells  include  proteolytic  processing,  phosphorylation,  sulfation, 
glycosylation,  ADP-ribosylation  and  as  reviewed  here,  acylation 
(103).  The  acylation  of  VV  polypeptides  in  many  ways  models 
cellular  systems,  having  similar  motifs  specifying  the 
modifications,  and  playing  analogous  roles  in  protein  function  and 
in  targeting.  Although  we  have  learned  much  from  these  proteins, 
there  is  still  much  work  to  be  performed  in  completing  their 
characterization. 
Through  our  efforts  to  characterize  the  L  1  R protein  we  have 
demonstrated  its  essentiality  to  the  virus  as  well  as  the 
significance  of  the  myristyl  modification  to  protein  function.  Our 
focus  has  now  shifted  toward  gaining  a  better  understanding  of 
the  protein:membrane  interaction.  With  a  knowledge  of  the 
membrane  topology  of  L  1  R  it  may  be  possible  to  dissect  functional 
domains  of  the  protein  and  gain  insight  into  the  molecular 
mechanism  of  action.  Additionally,  it  is  not  known  that  L  1  R  has 
any  protein  partners,  and  it  will  be  of  interest  to  determine  if 
there  are  any. 
The  roles  that  E7R,  G9R  and  A  16L play  in  the  VV  life  cycle 
are  unknown.  Current  efforts  involve  the  construction  of 
recombinant  viruses  in  which  these  genes  are  under  inducible 
control.  This  should  allow  us  to  ascertain  the  necessity  of  these 24 
proteins  to  the  virus.  If  significant,  we  would  then  further  the 
research  by  an  analysis  of  the  biological  role  the  myristyl 
moieties  play. 
Much  is  already  known  of  p37  and  the  significance  of  its 
palmitylation  (see  Chapter  3)  but,  based  on  recent  reports  of 
phospholipase  activity,  it  will  be  of  interest  to  discover  the  in 
vivo  substrates  for  this  enzyme.  Considering  the  numerous 
protein:membrane  interactions  necessary  for  envelopment  of  IMV 
to  form  EEV,  one  can  only  speculate  on  possible  roles  that a 
phospholipase  would  play  in  this  process. 
Both  gp42  (B5R)  and  the  gp23-28  (A33R)  are  essential  for 
dissemination  of  enveloped  virions,  but  why?  No  enzymatic 
activity  has  been  proposed  for  either  of  these  proteins,  and 
although  gp42  has  homology  to  complement  control  proteins,  that 
entire  domain  is  dispensable  for  the  formation  of  enveloped  virus. 
The  gp23-28  protein  does  not  share  homology  with  any  protein 
other  than  its  homologues  in  other  poxviruses  so  no  hypothesis 
regarding  function  can  be  made.  While  many  laboratories  are 
workin~ to  determine  the  function  of  these  proteins,  we  are 
investigating  the  importance  of  the  palmitate  modification.  Unlike 
p37,  which  requires  palmitylation  for  membrane  association, 
these  proteins  are  inserted  into  the  membrane  as  a  function  of 
their  primary  amino  acid  sequence.  In  other  systems,  the 
palmitylation  of  transmembrane  proteins  has  been  demonstrated 
to  be  dispensable  for  membrane  association  and  in  some  cases, 
function  (48),  while  in  others  it  is  necessary  for  both  (112). 
The  goals  of  this  thesis  are  to  identify  the  unknown  VV-
encoded  palmitylproteins  and  determine  their  sites  of 
modification.  The  major  VV-encoded  palmitylprotein,  p37,  will 
then  be  analyzed  further  for  the  significance  of  its  palmitate 
mod ification. 25 
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2.1  Introduction 
Palmitylation  of  proteins  involves  the  transfer  of  palmitate, 
a  16-carbon  saturated  fatty  acid,  from  palmityl-coenzyme  A  to 
cysteines,  serines  or  threonines  through  thioester  or  ester  linkage 
(55,  83,  85).  The  modification  is  made  post-translationally  and  in 
most  cases  by  an  unidentified  enzyme  or  enzymes  referred  to  as 
palmitylprotein  acyltransferases  (PATs)  (4,  88).  Some  reports 
suggest  that  at  least  for  a  small  number  of  proteins  a 
nonenzymatic  or  autocatalytic  mechanism  is  sufficient  to  mediate 
acyl  transfer  (3,  5,  7).  The  modification  is  reversible  in  vivo  and 
often  modulates  function  or  subcellular  localization  of  proteins. 
Although  many  cellular  and  viral  palmitylproteins  have  been 
characterized  regarding  site(s)  of  modification,  a  definitive 
structural  motif  specifying  palmitylation  of  proteins  has  not  been 
identified.  Palmitylproteins  have  been  separated  into  four 
separate  classes  based  on  membrane  topology,  prior  modification 
by  myristate  or  isoprenyl  moieties,  and  relative  to  the  termini, 
which  region  of  the  protein  is  modified  (74).  We  have  previously 
reported  that  the  palmitate  acceptor  residue(s)  of  proteins  may  be 
predicted  by  the  consensus  motif,  Hydro*1-12AACA (35). The 
hydrophobic  element  (Hydro*)  may  be  a transmembrane  domain,  a 
hydrophobic sequence  of  amino  acids  or  a  glycine  residue  that  has 
been  co-translationally  myristylated.  It  is  followed  by  a  1- to  12-
amino  acid  spacer  that  precedes  aliphatic  residues  (A) 
surrounding  the  palmitylated  cysteine  (C).  This  motif  is  based  on 
work  in  our  laboratory  as  well  as  the  work  of  others  (6,  46,  69, 
86,  90,  105). 
The  life  cycle  of  VV  is  well  characterized  (61)  (see  Figure 
1.1).  Upon  entry  into  cells  the  virus  expresses  a  distinct  subset  of 
early  genes  leading  to  uncoating  and  release  of  its  genome. 
Genome  replication  begins  followed  by  intermediate  gene 
expression.  The  intermediate  gene  products  primarily  serve  as 27 
transcription  factors  for  the  late  genes.  Following  late  gene 
expression,  virion  assembly  rapidly  ensues  in  concentrated 
cytoplasmic  foci  of  viral  DNA,  proteins  and  lipids,  termed 
viroplasm.  The  formation  of  the  first  virion  membrane  is 
controversial  in  that  it  is  not  entirely  clear  whether  it  is  derived 
from  the  intermediate  compartment  of  the  host  (93)  or  produced 
by  virus-specific  membrane  forming  machinery  (41). 
Nevertheless,  membrane  crescents  encircle  viroplasm  containing 
a single  copy  of the  genome  and  proteinaceous  components  of the 
core.  As  the  core  condenses  to  the  biconcave  shape  typical  of 
poxviruses,  the  first  infectious  virions  are  produced,  termed  IMV. 
Depending  on  the  strain  of virus  or  cell  system  used,  a  fraction  of 
IMV  ranging  from  25-400/0  is  targeted  to  the  TGN  where,  by  budding 
through  the  compartment,  two  additional  membranes  are  acquired, 
forming  lEV  (66).  lEV  may  exit the  cell  by  two  mechanisms.  The 
first  is  a  passive  release  that  is  not  well  characterized.  The 
second  mechanism  involves  the  formation  of  "actin  rockets"  that 
propel  the  virus  unidirectionally  through  and  out  of  the  cell, 
sometimes  directly  into  neighboring  uninfected  cells  (17).  Outside 
of  the  cell,  virions  may  remain  attached  (or  reattach)  to  the 
plasma  membrane  or  be  released  into  the  extracellular 
environment.  Virions  attached  to  the  cell  are  referred  to  as  CEV, 
while  those  free-floating  in  the  extracellular  environment  are 
refe rred  to  as  EEV. 
VV  serves  as  an  ideal  model  system  for  the  study  of  protein 
processing  for  several  reasons:  VV  proteins  (or  exogenous 
proteins  expressed  either  transiently  from  transfected  plasmids 
or  from  recombinant  VV)  are  subject  to  modifications  typical  of 
mammalian  systems,  to  include  sulfation  (65),  phosphorylation, 
ADP-ribosylation,  glycosylation  and,  as  highlighted  here, 
acylation  (103).  Its  genes  are  expressed  in  the  cytoplasm  without 
mRNA  processing,  allowing  conceptual  translation  directly  from 
genomic  sequence.  We  have  previously  observed  that  many  VV 
proteins  are  acylated  providing  numerous  subjects  for  study 28 
In  this  chapter  we  report  on  the  identification  of  previously 
unknown  palmitylproteins  encoded  by  the  A22R,  A36R  and  AS6R 
(COP  strain)  ORFs  of VV.  Then,  by  a biochemical  characterization 
of  the  proteins  and  comparison  to  the  palmitylation  motif, 
Hydro*1-12AACA, we  were  able  to  accurately  predict  the 
modification  sites  for  gp4S-S0  (A36R),  gp86  (AS6R),  gp42  (BSR) 
and  p37  (F13L). 
2.2.  Materials and  Methods 
2.2.1  Cells  and  Viruses 
BSC40  (African  green  monkey  kidney)  and  RK13  (rabbit 
kidney)  cell  lines  were  cultured  in  Eagle's  minimal  essential 
medium  supplemented  with  100/0  (v/v)  fetal  calf  serum,  2  mM  L-
glutamine,  10  Jlg/ml  gentamycin-sulfate  (MEM-10  LG/GS)  at  37°C 
in  a  SOlo  C02  humidified  atmosphere.  Upon  infection  with  VV,  the 
cells  were  then  cultured  in  Eagle's  minimal  essential  medium 
supplemented  with  2  mM  L-glutamine,  10  Jlg/ml  gentamycin-
sulfate  (MEM  LG/GS)  at 37°C  in  a S%  C02  humidified  atmosphere. 
The  COP,  IHO-J,  and  WR  strains  of  VV  were  routinely  propagated 
and  titered  in  BSC40  cells  as  previously  described  (24).  The 
recombinant  VV,  vTF7-3  (30),  was  used  for  transient  expression 
of  genes  cloned  into  the  plasmid  vector,  pTM1 :6xHis  (described 
below).  This  virus  contains  of copy  of  T7  gene  1 inserted  at the 
thymidine  kinase  locus  of the  VV  genome  and  expresses  T7  RNA 
polymerase  nearly  constitutively  during  infection.  Genes 
downstream  of  a  T7  promoter  are  expressed  to  high  levels  when 
present  in  the  cytoplasm  of  vTF7-3-infected  cells.  Standard 
methods  were  used  to  propagate  and  titer  this  virus  as  well. 29 
2.2.2  Metabolic  Labeling  of 	VV  Proteins  with  [3H]-Myristic 
Acid  and  [3H]-Palmitic  Acid 
Labeling  of  COP,  IHD-J  and  WR  acylproteins:  [9,10  3H(N)]-
Myristic  acid  (50  Ci/mM;  [3H]-MA)  and  [9,  10  3H(N)]-palmitic  acid 
(50  Ci/mM;  [3H]-PA),  purchased  as  ethanolic  solutions,  were  dried 
by  nitrogen  overflow.  The  lipids  were  then  resuspended  in 
dimethyl  sulfoxide  (DMSO)  at  a  concentration  of  10  J.1Ci/J.11.  BSC40 
cells  were  grown  to  confluency  in  35  mM  wells  (106  cells/well). 
The  cells  were  synchronously  infected  with  either  COP,  IHD-J  or 
WR  strains  of  VV  at  a  multiplicity  of  infection  (moi)  of  10.  At  4 
hours  post-infection  (hpi),  [3H]-MA  or  [3H]-PA  was  added  to  a 
final  concentration  of  100  J.1Ci/ml  in  no  more  than  10  J.11  of  DMSO. 
At  24  hpi  the  cells  were  harvested  and  resuspended  in  reducing 
sodium  dodecylsulfate-polyacrylamide  gel  electrophoresis  (SDS-
PAGE)  sample  buffer  and  frozen  until  needed. 
Time  course  labeling:  BSC40  cells  were  grown  to  confluency 
in  35  mM  wells.  The  cells  were  synchronously  co-infected  with 
COP  and  WR  strains of VV  at  a moi  of  10  each  (final  moi  =  20). 
Labeled  lipids  were  added  to  a  final  concentration  of  100  J.1Ci/ml 
in  no  more  than  10  J.11  of  DMSO.  The  labeling  periods  included  the 
0-1,  1-2,  2-4,  4-8,  and  8-24  hpi  time-points.  Infected  cells  were 
immediately  harvested  at  the  end  of  the  labeling  periods  and 
resuspended  in  reducing  SDS-PAGE  sample  buffer  and  frozen  until 
needed. 
Labeling  infected  cells  for  subcellular  fractionation  and 
purification  of  IMV  and  EEV:  BSC40  cells  were  grown  to 
confluency  on  150  mM  tissue  culture  plates  (2x107  cells).  The 
cells  were  co-infected  with  the  COP  and  WR  strains  of VV  at  a 
moi  of 10  each  (final  moi  =  20).  At  4 hpi  [3H]-PA  was  added  to  a 
final  concentration  of  100  IlCilml.  At  24  hpi  both  the  culture 
medium  and  the  infected  cells  were  collected  for  purification  of 
IMV  and  EEV  and  for  subcellular  fractionation  of  VV 30 
palmitylproteins.  The  culture  supernatant  was  clarified  of 
cellular  debris  by  centrifugation  at  700  x  g  for  20  minutes. 
Labeled  EEV  was  then  pelleted  from  the  clarified  culture  medium 
by  centifugation  at  100,000  x  g  for  30  minutes.  The  EEV  pellet 
was  resuspended  in  500  J,LI  of  phosphate-buffered  saline  (137  mM 
NaCI, 2.7 mM  KCI,  4.3 mM Na2HP04·7H20, 1.4 mM  KH2P04; PBS), 
titered,  and  then  frozen  until  needed.  The  infected  cells  were 
resuspended  in  6  ml  of  PBS,  rapidly  frozen,  then  thawed  to  lyse 
cells.  To  ensure  cell  lysis  the  cellular  extracts  were  vortexed 
vigorously  while  still  partially  frozen  using  the  ice  crystals  to 
homogenize  the  cell  extracts.  One  ml  of  the  infected  cell  lysate 
was  set  aside  for  subcellular  fractionation.  IMV  was  purified  from 
the  remaining  5  ml  of  cell  lysate  by  using  CsCI  gradients 
following  techniques  standard  for  VV  (67). 
2.2.3  Differential 	Centrifugal  Subcellular  Fractionation  of 
VV-Infected  Cell  Extracts 
From  the  1-ml  fraction  of  infected  cell  Iysates 
(approximately  3x106  cells),  100  J,LI  was  removed  and  set  aside  as 
the  total  cell  extracts  (TCE).  The  remaining  900  J,LI  was 
centrifuged  at  700  x  g  for  10  min  to  pellet  nuclei.  The  pellet  was 
resuspended  in  900  J,LI  of  PBS  and  frozen  until  needed.  The 
supernatant  was  centrifuged  at  20,000  x  g  for  30  min  to  pellet 
cytosolic  membranous  components  and  whole  virions.  The  pellet 
(P20)  was  resuspended  in  900  J,LI  of  PBS  then  frozen  until  needed. 
The  supernatant  containing  the  soluble  components  of  the 
cytoplasm  (S20)  was  transferred  to  another  microfuge  tube  and 
then  frozen  as  well. 31 
2.2.4 Sodium 	 Oodecylsulfate-Polyacrylamide  Gel 
Electrophoresis  (SOS-PAGE),  Affinity  Blots  and 
Fluorography  of  VV  Proteins 
For  resolution  of  VV  proteins  by  SOS-PAGE,  all  samples 
were  resuspended  in  1  X reducing  SOS-PAGE  sample  buffer.  To 
minimize  reduction  of  the  thioester-bonded  palmitate,  samples 
were  heated  to  70°C  for  1  min,  then  rapidly  cooled  to  4°C  before 
loading  the  gels.  All  gels  used  were  12.5%  acrylamide:bis-
acrylamide  (30:0.8).  For  affinity  blots,  SOS-PAGE  gels  were 
electroblotted  to  nitrocellulose  by  standard  western  blotting 
techniques  (99)  and  then  probed  using  Ni+-activated  horseradish 
peroxidase,  which  binds  histidine-tagged  proteins  (see  below). 
The  blots  were  developed  by  using  chemiluminescent  reagents  and 
exposure  to  film.  To  detect  [3H]-PA-or  [3H]-MA-labeled  proteins 
in  gels,  the  gels  were  first  dehydrated  by  immersion  in  DMSO  for 
30  minutes.  The  gels  were  then  impregnated  with  diphenyloxazole 
(PPO)  by  immersion  in  a 22.2%  PPO:OMSO solution  for  1 hour  (13). 
The  PPO  was  precipitated  in  the  gel  by  immersion  in  water  for  30 
minutes.  The  gels  were  then  dried  and  exposed  to  film. 
2.2.5 Identification  of  Candidate  Palmitylproteins 
The  identification  of  candidate  VV-encoded  palmitylproteins 
was  made  using  a number of  criteria:  We  have  observed  (see 
Results)  that  VV  palmitylproteins  are  primarily  "late"  proteins, 
have  relative  molecular  masses  of  14,  17,  23-28  (a  single 
protein),  37,  42,  46,  86,  and  94  kOa,  as  determined  by  SOS-PAGE, 
and  are  specific for  EEV.  Focusing  then,  on  VV  gene  products  that 
matched  these  criteria,  we  then  scanned  the  conceptually 
translated  polypeptides  from  the  COP  strain  of  VV  for  sequences 
that  fit  with  our  previously  reported  palmitylation  motif, 
Hydro*1-12AACA.  "Hydro"  may  be  a  previously  myristylated 32 
glycine,  a  transmembrane  domain,  or  a  hydrophobic  stretch  of 
amino  acids  usually  at  least  10  residues  in  length.  The 
hydrophobic  element  is  usually  followed  by  a  1- to  12-amino  acid 
spacer then  a cysteine  (C)  residue  (or  residues)  surrounded  by 
aliphatic  amino  acids  (A). 
2.2.6 Cloning  and  Transient  Expression  of  Candidate 
Palmitylproteins 
All  the  candidate  palmitylprotein  genes  were  cloned  into 
pTM1 :6xHis,  constructed  as  follows:  The  LSR  gene  of  VV  was 
amplified  from  IHD-J  genomic  DNA  by  polymerase  chain  reaction 
(PCR)  using  primers  LSR-S'  (S'-CCGGAATICATATGGAGAATGTTCCT 
AATG-3'),  and  LSR-3'6xHis  (S'-CCAA  TGCA TIGGTICTGCAGTTTCAT 
CAGTGGTGGTGGTGGTGGTGGGATCCTCTGCGAAGAACATCG-3'). The 
PCR  product  was  treated  with  restriction  enzyme  EcoRI, 
generating  an  overhang  at the  S'  end  of  the  product  and  leaving  the 
3'  end  blunt,  and  then  ligated  into  EcoRIIStul-restricted  pTM1 
producing  the  plasmid  pTM1 :LSR-6xHis.  This  placed  the  S'  end  of 
the  LSR  gene  downstream  of  the  T7  promoter  and  encephalo-
myocarditis  virus  S'-untranslated  regionlinternal  ribosomal  entry 
site  (EMC-Ieader)  on  pTM1.  The  normal  LSR  stop  codon  was  not 
included  in  the  PCR  primer  and  was  instead  replaced  by  sequences 
that,  following  transcription  and  translation,  resulted  in  the 
addition  of  a  glycine  and  a  serine  followed  by  six  histidines  at  the 
carboxy  terminus  of  the  protein.  The  remaining  candidate 
palmitylprotein  genes  were  cloned  into  pTM1 :LSR-6xHis.  To  do 
this,  the  LSR  coding  sequence  was  excised  by  restriction  with 
Ndel and  BamHI,  leaving  the  6-histidine  tag  sequence  intact  on  the 
plasmid.  All  other  candidate  palmitylprotein  genes  were  PCR-
amplified  from  IHD-J  genomic  DNA  with  the  exception  of the  AS6R 
gene,  which  was  amplified  from  COP  and  WR  genomic  DNA  as  well 
as  IHD-J.  The  A  14L  gene  was  amplified  using  primers  A  14L-S'  (S'-
CCGGAATTCATATGGACATGATGCTIATG-3') and  A14L-3'  (S'-33 
GCGGGATCCGTTCATGGAAATATCGCTATG-3'); the A22R gene was 
amplified  using  primers  A22R-S'  (S'-CCGGAATTCATATGTCGTCA 
CCGATG-3') and  A22R-3' (S'-GCGGGATCCCATTTTTTTTATGTAATTC 
CTAG-3');  the  A33R  gene  was  amplified  using  primers  A33R-S' 
(S'-CCGGAA  TTCATATGATGACACCAG-3') and A33R-3' (S'-GCGGGA 
TCCGTTCATTGTTTTAACAC-3');  the  A34R  gene  was  amplified  using 
primers A34R-S'  (S'-GCATCAGCCCCATATGAAATCGCTTAAT  AGACAA 
ACTGT  AAG-3')  and  A34R-3' (S'-GCGGGATCCCTTGT  AGAA  TTTTTT  AA 
CAC-3');  the  A36R  gene  was  amplified  using  primers  A36R-S'  (S'-
CCGGAA  TTCATATGATGCTGGTACC-3') and A36R-3' (S'-GCGGGATCCC 
ACCAATGATACG-3');  the  AS6R  gene  was  amplified  using  primers 
AS6R-S'  (S'-CCGGAATTCATATGACACGATTACC-3')  and  AS6R-3'  (S'-
GCGGGATCCGACTTTGTTCTCTG-3'); the  BSR gene was amplified 
using  primers BSR-S'  (S'-GCATCAGCCCCATATGAAAACGATTTCCGTT 
GTTACGTT-3') and BSR-3' (S'-GCGGGATCCCGGTAGCAATTTATGG-
3');  the  F13L  gene  was  amplified  using  primers  F13L-S'  (S'-GCATC 
AGCCCCATATGTGGCCATTTGC-3') and F13L-3' (S'-GCGGGATCCAATT 
TTTAACG-3').  All  the  PCR  products  were  digested  with  restriction 
enzymes  Ndel and  BamHI and  ligated  into  Ndel/BamHI-digested 
pTM1 :LSR-6xHis,  producing  plasmids  pTM1 :A14L-6xHis, 
pTM1 :A22R-6xHis,  pTM1 :A33R-6xHis,  pTM1 :A34R-6xHis, 
pTM1 :A36R-6xHis,  pTM1 :AS6R(COP)-6xHis,  pTM1 :AS6R(IHD-J)-
6xHis,  pTM1 :AS6R(WR)-6xHis,  pTM1 :BSR-6xHis,  and  pTM1 :F13L-
6xHis. 
Transient  expression  of  the  candidate  palmitylproteins  was 
facilitated  by  use  of  the  vTF7-3  recombinant  VV.  BSC40  cells 
were  grown  to  confluency  on  3S-mm  wells  in  6-well  tissue 
culture  plates  (106  cell/well).  The  cells  were  infected  with 
vTF7-3  at  a  moi  of  10.  Following  a  1-h  virus  adsorption  period, 
the  inoculum  was  aspirated  and  replaced  with  SOO  III  of  MEM-E 
LG/GS  containing  10  Ilg  of  plasmid  DNA  complexed  with  the 
transfection  reagent  DMRIE-C  (Gibco-BRL).  At  4  hpi  (also  4  h  post-
transfection)  an  additional  SOOIlI  of  MEM-E,  LG/GS  was  added.  If 
label  was to  be  added  it  was  added  with  the  SOO  III  of MEM-E, 
LG/GS  at 4  hpi.  At  24  hpi  the  cells  were  washed  free  of the  tissue 34 
culture  plates  using  the  culture  medium.  The  cells  were  pelleted 
from  the  medium  by  centrifugation  at  700  x  g  for  10  min.  The 
cells  were  resuspended  in  100  J.LI  of  PBS  containing  5  U of  ONase  I 
to  reduce  the  viscosity  of  the  cell  lysate,  following  lysis  by  3 
cycles  of  freezing  and  thawing,  to  facilitate  gel  loading.  Eighty  J.11 
of  each  of  the  cell  Iysates  were  set  aside  for 
immunoprecipitations.  The  remaining  20  J.11  of  cell  Iysates  were 
made  1  X  reducing  SOS-PAGE  sample  buffer by  addition  of 4  J.11  of 
6X  reducing  SOS-PAGE  sample  buffer  before  loading  gels. 
2.2.7  Immunoprecipitation  of  Proteins 
EightY-J.11  samples  of  infected  cell  Iysates  (approximately 
8.0x105  cells),  labeled  during  infection  with  [3H]-PA,  were 
diluted  to  1  ml  with  radio-immunoprecipitation  assay  (RIPA) 
buffer  (1%  w/v  sodium  deoxycholate,  1%  vlv  Triton  X-100,  0.2% 
w/v SOS,  150  mM  sodium  chloride,  50  mM  Tris-HCI,  pH  7.4). 
Histidine-tagged  proteins  were  immunoprecipitated  by  addition  of 
an  anti-6-histidine  monoclonal  antibody  (Qiagen)  and  Protein  A-
coated  sepharose  beads.  The  reactions  were  performed  on  a  rotary 
mixer  at  4°C  for  18  h.  The  immunoprecipitates  were  washed 
numerous times with  RIPA  buffer then  resolved  by  SOS-PAGE.  The 
gels  were  fluorographed  in  PPO:OMSO  and  exposed  to  film  for 
detection. 35 
2.2.8 Mutagenesis  of  Palmitate  Acceptor  Residues 	in  VV 
Palmitylproteins 
Oligonucleotide  {oligo}-directed  mutagenesis  of  VV 
palmitylprotein  genes  on  pTM1 :6xHis  plasm ids  followed  the 
method  of  Kunkel  et a/{51}.  All  plasm ids  resulting  from  the 
mutagenesis  reactions  were  identical  to  their  parental  plasmids 
with  the  exception  of  the  mutated  codon  and  novel  restriction 
sites  engineered  for  preliminary  screening.  The  restriction  sites 
did  not  alter  the  coding  potential  of  the  genes.  All  mutations  were 
confirmed  by  DNA  sequencing.  The  codon  encoding  cysteine  99 
{C99,  numbering  from  the  initiating  methionine}  of  A22R  was 
mutated  to  encode  serine  using  oligo  A22R-C99S  {5'-GCCAAAG 
TGATCAGCGTCTCGCCTGTC-3'}  producing plasmid pTM1 :A22R-C99S. 
The  codon  encoding  C36  of  A33R  was  mutated  to  encode  serine 
using  oligo  A33R-C36S  {5'-GTGATTGGTCTATCGATT  AGAAT  ATCT 
ATGG-3'}  producing  plasmid  pTM1 :A33R-C36S.  The  codon  encoding 
C19  of A36R  was  mutated  to  encode  serine  using  oligo  A36R-C19S 
(5'-GGAACAATACT  AGTATCTTATAT  ATTAT  ATATTTGTAGG-3') 
producing  plasmid  pTM1 :A36R-C19S.  The  codon  encoding  C25  of 
A36R  was  mutated  to  encode  serine  using  oligo  A36R-C25S  {5'-
GTTATAT  ATT  ATATATCTCGAGGAAAAAGATACG-3'}  producing 
plasmid  pTM1 :A36R-C25S.  The  codon  encoding  C301  of  85R was 
mutated  to  encode  serine  using  oligo  85R-C301S  (5'-GTTATAGTA 
TTAGTCTCGAGTTGTGACAAAAATAATGAC-3')  producing  plasmid 
pTM1 :85R-C301 S.  The  codon  encoding  C303  OF 85R was  mutated to 
encode  serine  using  oligo  85R-C303S  (5'-GTTATAGTATT  AGTTTGC 
TCGAGTGACAAAAATAATGAC-3')  producing  plasmid  pTM1 :85R-
C303S.  An  internal  region  of the  F13L  ORF  on  pTM1:F13L-6xHis 
containing  codons  for  C185  and  C186  was  replaced  with  the 
homologous sequence  from  pDG5.3  {33}  {see  Chapter 3}.  This 
plasmid  contains  a  copy  of  F13L  but  harbors  mutations  leading  to 
the  replacement  of  C185/C186  with  serines  without  altering  the 
otherwise  wild-type  sequence.  This  produced  plasmid  pTM1 :F13L-
C185/6S.  No  mutations  were  made  to  the  A56R  plasmid.  Instead, 36 
clones of A56R from  COP,  IHD-J  and  WR  DNA were  made.  The COP 
and  WR  sequences of the  A56R  gene  are  known  (32,  92).  The  IHD-J 
A56R  DNA was  sequenced for comparison  to  WR  and  COP.  All 
plasmids  were  sequenced  through  the  cloned  genes  to  ensure 
accuracy  of the  sequence. 
2.3  Results 
2.3.1  Analysis  of  VV  Acylproteins 
VV  potentially  encodes  more  than  200  proteins  expressed  in 
three  distinct  temporal  classes,  early,  intermediate  and  late.  To 
limit  the  number  of  proteins  to  target  for  our  study  we  performed 
a  time-course  labeling  experiment  with  [3H]-PA  and  [3H]-MA  to 
determine  their  temporal  class.  BSC40  cells  were  grown  to 
confluency  on  35-mm  wells  in  6-well  plates.  They  were  then 
synchronously  infected  with  the  COP  and  WR  strains  of VV  at an 
moi  of  10.  The  cells  were  co-infected  so  that  all  VV 
palmitylproteins  and  myristylproteins  could  be  detected  at  the 
same  time.  COP  does  not  produce  the  92-kDa  myristylprotein,  but 
produces  an  86-kDa  protein  not  present  in  WR-infected  cells.  The 
infected  cells  were  labeled  by  addition  of  [3H]-PA  or  [3H]-MA  at 
100  JlCilml  from  0-1,  1-2,  2-4,  4-8  and  8-24  hpi.  The  infected 
cells  were  harvested  at  the  end  of each  labeling  period.  The  total 
cell  extracts  were  resolved  by  SDS-PAGE  followed  by 
fluorography  and  then  exposed  to  film.  With  the  exception  of  a  14-
kDa  protein  that  incorporated  label  from  both  myristic  and 
palmitic  acids  in  the  1-2  hpi  labeling  period,  all  other 
acylproteins  encoded  by  VV  appear  to  be  "late"  proteins  (Figure 
2.1).  The  14-kDa  acylprotein  continued  to  incorporate  label  from 
2-8  hpi  but  was  nearly  absent  in  the  8-24  hpi  labeling  period.  All 
other  VV  acylproteins  incorporated  label  in  the  2-4,  4-8  and  8-24 37 
Figure  2.1. SDS-PAGE  analysis  of time-course  labeled  VV 
acylproteins.  8SC40  cells  were  co-infected  with  WR  and  COP 
strains  of  VV  at  a  combined  moi  of  20.  Cells  were  labeled  with 
[3H]-PA  (A  and  8)  or  [3H]-MA  (C  and  D)  for time  periods  as 
indicated  above  the  gel  lanes  (hours  post-infection).  Identical  gels 
were  treated  with  neutral  hydroxylamine  to  cleave  thioester-
bonded  fatty  acids  (8 and  D).  All  gels  were  fluorographed  by 
impregnation  with  PPO  prior  to  film  exposure.  Note  the  14-kDa 
acylprotein  recalcitrant  to  hydroxylamine  treatment  in  8  and  D. 38 
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hpi  labeling  periods.  To  distinguish  between  authentic 
myristylproteins  and  those  that  were  labeled  through 
interconversion  to  palmitic  or  other  long-chain  fatty  acids, 
identical  gels  were  treated  with  hydroxylamine  before 
fluorography  (Figure  2.1 C).  Vaccinia  encodes  palmitylproteins 
with  apparent  molecular  masses  of  14,  17,  23-28  (a  single 
glycoprotein  with  a  common  peptide  backbone  migrating  as  three 
distinct  species),  37,  42,  46,  and  94  kDa  (Figure  2.1 A). 
Additionally,  the  COP  strain  produced  a  86-kDa  protein  that  was 
not  detectable  in  the  WR  or  IHD-J  infected  cell  extracts  (Figure 
2.2A).  The  23-28-,  37-,  and  42-kDa  proteins  have  previously  been 
reported  to  be  encoded  by  the  A33R  (81),  F13L  (40)  and  85R  (45) 
ORFs  respectively.  The  identities  of  the  14-,  17-,  46-,  86-,  and 
94-kDa  palmitylproteins  are  unknown  and  represent  the  topic  of 
this  chapter. 
The  myristylproteins  migrated  with  apparent  molecular 
masses  of  14,  17,  25,  36,  39,  and  92  kDa  (Figure  2.1 D).  The  92-kDa 
myristylprotein  was  not  produced  by  the  COP  strain  (Figure  2.2A) 
and  most  likely is  the  ATI  protein  encoded  by  the  A25L  ORF of WR 
and  IHD-J  as  previously  reported  (31,  59).  The  25-kDa 
myristylprotein  is  encoded  by  the  L  1  R ORF  and  has  been  the 
subject  of  numerous  studies  (29,  71,  72,  111).  We  have  recently 
reported  that  the  17-,  36-,  and  39-kDa  proteins  are  encoded  by 
the  E7R,  A  16L and  G9R  ORFs  respectively  (57).  In  a single  report, 
the  14-kDa  myristylprotein  was  identified  as  the  product  of  the 
A  14L ORF  (77)  - a finding  that  is  not  supported  by  our  work  (see 
section  2.3.6  and  Figure  2.6). 
2.3.2 Subcellular  Fractionation  and  Virion  Association  of  VV 
Acylproteins 
The  L  1  R  myristylprotein  is  known  to  be  a  component  of  both 
IMV and  EEV  (70,  72).  The  A33R  (81),  85R (45,  109)  and  F13L (9) 2 
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Figure 2.2. Comparison of acylproteins encoded by COP,  IHO-J  and 
WR  strains of VV.  BSC40 cells were infected with COP,  IHO-J  or 
WR  strains of VV at an  moi of 10. Cells were labeled by addition 
of [3H]-PA  or [3H]-MA from 4 to 24 hpi. Total cellular extracts 
were resolved by SOS-PAGE  and  acyl proteins were detected by 
exposure of PPO-impregnated gels to film (A and  B).  An  identical 
gel was treated with neutral hydroxylamine to cleave thioester-
bonded fatty acids (B). Note the absence of a 92-kOa 
myristylprotein ([3H]-MA) from COP  extracts. Also note the 
presence of an  86-kDa palmitylprotein in  COP  extracts that is 
absent from IHO-J  and  WR  extracts. 
palmitylproteins are  known to be  specific for TGN  membrane-
enveloped virions (lEV,  CEV and  EEV)  and are found in TGN 
membranes prior to envelopment (84). To determine the 
intracellular location of the other acylproteins, we  fractionated 
infected, labeled cells by differential centrifugation to yield a 
nuclear fraction, particulate cytosolic fraction (containing whole 
virions and cytosolic membranous components) and soluble 41 
fraction.  We  also  purified  IMV  and  EEV  from  labeled  cells.  The  L  1  R 
myristylprotein  was  present  in  the  nuclear  fraction  and  the 
membrane  fraction,  which  also  contains  whole  virions  (Figure 
2.38).  It was  also  associated  with  IMV  and  EEV.  All  other 
myristylproteins  were  found  in  the  soluble  fraction  of  cells 
although  a small  amount  of  the  G9R  protein  is  present  in  IMV  also. 
All  VV  palmitylproteins  found  in  total  cell  extracts  were  present 
in  the  nuclear  fraction  and  the  membrane  fraction  and  were 
specific  for  EEV  (Figure  2.3A).  Two  additional  palmitylproteins 
with  apparent  molecular  masses  of  20  and  22  kDa,  which  were  not 
obvious  in  the  total  cell  extracts,  were  present  on  EEV  as  well.  No 
VV  palmitylproteins  were  found  to  be  soluble  or  IMV-associated. 
2.3.3  Identification  of  Candidate  Palmitylproteins 
To  identify  candidate  palmitylproteins  we  considered  that 
VV  palmitylproteins  are  of  the  late  temporal  class,  are  specific 
for  lEV,  CEV  and  EEV,  and  most  likely  contain  hydrophobic 
sequences  mediating  membrane  association.  We  then  scanned  the 
sequence  of  the  COP  strain  (which  is  entirely  sequenced)  (32)  for 
ORFs  preceded  by  late  promoters  and  encoding  proteins  whose 
predicted  mass  corresponded  to  SDS-PAGE  observed  mobility  of 
VV  palmitylproteins.  These  sequences  were  then  analyzed  for 
hydrophobic  regions  and  for  cysteines  that  were  within  the 
consensus,  Hydro*1-12AACA.  8y these  criteria  the  following  ORFs 
were  identified  as  potentially  encoding  palmitylproteins:  A  14L, 
A22R,  A33R,  A34R,  A36R,  A56R,  85R  and  F13L  (Figure  2.4).  It has 
been  previously  reported  that  the  products  of  the  A33R  (81),  85R 
(45)  and  F13L  (38,  40)  ORFs  are  palmitylproteins  and  led  us  to 
conclude  that  our  criteria  were  sufficient.  Additionally,  the 
products  of  the  A33R  (81),  A34R  (23),  A36R  (62),  A56R  (68),  85R 
(25,  45),  and  F13L (38,  40)  ORFs  are  specific for  lEV,  CEV  and  EEV 
further  supporting  these  as  candidate  palmitylproteins. 42 
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Figure 2.3. Differential centrifugation  subcellular fractionation of 
VV acylproteins. BSC40 cells were co-infected with COP  and  WR 
strains of VV at a combined moi of 20. Cells  were labeled with 
[3H]-PA (A) or [3H]-MA (B) from 4 to 24 hpi.  EEV  was  purified from 
the culture medium. A portion of the total cell extracts (TCE)  was 
fractionated to yield a nuclear fraction (NP), a particulate 
cytosolic fraction (P20), containing intracellular membranes and 
whole virions, and a soluble cytosolic fraction (S20). IMV  was 
purified from infected cells. Fractions and  equal titers of IMV and 
EEV  were resolved by SDS-PAGE.  Gels  were impregnated with PPO 
prior to film exposure to detect [3H]-PA-or [3H]-MA-labeled 
proteins. 43 
Gene  Praroter  Peptide Sequence  Size 
A14L  A'.l'lTAAAAT1Tl'lMA:1\!  WIUiT.JYiC*IFAFIDFSKS  10-kDa(15) 
A22R  TMATA1ICC (35 )CAA'l'CITl'AAm  LYm'SMKVIC*y5PVMSGNSY  21-kDa(21) 
A33R  ~~MG  KNKRKRVIGI.C*m lOOISLL  _21-kDa(23-28) 
A34R  AT1TATl'I"l'IDr'lMMG  ,HIKEErMPSl¥::*ANGWIQYDKH  20-kDa(21-24) 
A36R  TMATA(9) TMATA (31) GMAm  Vl'\NAGI'ILVC*YILYIC*RKK  25-kDa(45-50) 
A56R  ~MG Tl·U$AVAIFG *ITYYIC*NKR  35-kDa(72-86) 
B5R  ~~ IFLISVIVLVC*SC*DKNNDQY  35-kDa(42) 
F13L  ~'lMAW  SWINLC*SAAC*C*LPVSTAYH  41-kDa(37) 
Figure 2.4. Identification of candidate VV palmitylproteins. Using 
a conceptual translation of the VV genome (COP strain), VV 
proteins were evaluated as  candidates for palmitylation. Proteins 
whose promoters contain the consensus "late" start sequence 
upstream of the start ATG  (bolded) were considered as  candidates. 
Late promoter elements are underlined. Numbers in parentheses 
indicate the number of nucleotides that separate the nucleotides 
shown. The A56R gene does not contain a consensus "late" 
promoter but is  included for additional reasons (see text). The 
peptide sequences of VV late proteins were inspected for 
homology to the palmitylation motif Hydro*1-12AACA. Proteins 
containing hydrophobic regions (underlined) with cysteine 
residues in  an  aliphatic environment (C*) were considered for 
further analysis. The predicted size of the protein is  compared to 
the SDS-PAGE  observed mobility (numbers in  parentheses under 
"Size"). 44 
2.3.4 Transient  Expression  and  Palmitylation  of  Candidate 
Palmitylproteins 
The  ORFs  for  each  candidate  palmitylprotein  were  PCR 
amplified  from  VV  genomic  DNA  and  cloned  into  a  modified  pTM1 
vector,  pTM1 :6xHis.  This  vector  contains  sequences  that, 
following  expression,  result  in  the  addition  of  a  carboxy-terminal 
6-histidine  tag  on  each  of  the  candidate  palmitylproteins.  The  T7 
promoter  and  encephalomyocarditis  virus  5'  untranslated  region 
(EMC  leader)  are  left  intact  as  well.  Following  infection  of  cells 
with  vTF7-3  (a  T7  polymerase-expressing  recombinant  vaccinia) 
the  T7  promoter  is  recognized  by  the  virus-produced  T7 
polymerase  mediating  high-level  transcription.  The  EMC  leader 
present  on  the  transcript  serves  as  an  internal  ribosomal  entry 
site  mediating  cap-independent  translation.  For  these 
experiments,  106  BSC40  cells  were  infected  with  vTF7-3  at  an 
moi  of  10  followed  by  transfection  of  10  J.1g  of  each  of  the 
plasmid  DNAs  in  separate  wells  of  6-well  plates  (35-mm  wells). 
At  4 hpi  [3H]-PA  was  added  to  a  final  concentration  of  100  J.1Ci/ml 
in  the  culture  medium.  At  24  hpi  the  infected  cells  were  harvested 
and  resuspended  in  100  J.1I  of  PBS.  Ten  J.1I  of each  sample  was 
resolved  by  SDS-PAGE  on  two  identical  gels.  The  first  gel  was 
electroblotted  to  nitrocellulose  and  probed  with  Ni+-activated 
horseradish  peroxidase,  which  binds  to  the  6-histidine  tag  on  the 
transiently  expressed  proteins.  The  blot  was  then  developed  by 
chemiluminescent  reagents  and  exposure  to  film.  The  other  gel 
was  fluorographed  in  PPO:DMSO,  dried  and  exposed  to  film  for 
detection  of  all  [3H]-PA-labeled  proteins  present  in  the  total  cell 
extracts.  The  remaining  80  J.1I  of  sample  was  immunoprecipitated 
by  using  an  anti-6-histidine  monoclonal  antibody.  The 
immunoprecipitated  proteins  were  resolved  by  SDS-PAGE.  The  gels 
were  fluorographed  in  PPO:DMSO,  dried  and  exposed  to  film  as 
above. 45 
The  affinity  blot  (referring  to  the  Ni+-activated  horseradish 
peroxidase-probed  blot)  demonstrated  that  all  the  proteins  were 
efficiently  expressed  by  the  vTF7-3/pTM1 :6xHis  system  (Figure 
2.5A).  We  observed  the  following:  A  14L  encodes  a  protein  of 14 
kDA  with  minor  species  migrating  at  approximately  16  and  22 
kDa;  A22R  encodes  a 21-kDa  protein;  A33R  encodes  three  proteins 
migrating  at  23,  25,  and  28  kDa;  A34R  encodes  two  proteins 
migrating  at 22  and  24  kDa;  A36R  encodes  a protein  poorly 
resolving  between  45  and  SO  kDa;  AS6R  encodes  possibly  three 
proteins  resolving  between  72  and  86  kDa;  85R  encodes  a  42-kDa 
protein  and  is  present  in  a  higher  molecular  weight  complex  of 
approximately  94  kDa;  and  F13L  encodes  a 37-kDa  protein.  The 
fluorograph  of the  same  cell  extracts,  labeled  with  [3H]-PA, 
demonstrate  that the  A14L,  A34R  and  AS6R  (IHD-J  and  WR  strains) 
proteins  did  not  incorporate  the  label  above  background  levels, 
suggesting  that  they  are  not  palmitylproteins  (Figure  2.58  and 
2.SC).  Proteins  expressed  from  A22R,  A33R,  A36R,  A56R  (COP 
strain),  8SR,  and  F13L  incorporated  the  label  significantly  above 
background  levels,  suggesting  that these  ORFs  encode 
palmitylproteins.  It  has  been  previously  demonstrated  that  the 
A33R, .8SR  and  F13L  genes  encode  palmitylproteins,  while  A22R, 
A36R  and  A56R  (COP  strain)  are  newly  discovered 
palmitylproteins. 
2.3.S  Identification 	of  Palmitate-Modified  Residues  of  VV 
Palmitylproteins 
To  narrow  the  number  of  residues  that  might  be  subject to 
palmitylation,  each  of  the  VV  palmitylprotein  sequences  was 
examined  for  cysteine  residues  that  fell  within  the  context  of  the 
palmitylation  motif,  Hydro*1-12AACA.  We  also  considered  that 
those  regions  of proteins  exposed  to  the  lumenal  compartment  of 
intracellular  organelles  or  the  extracellular  environment  were 
unlikely  to  be  palmitylated  due  to  the  reducing  nature  of  those 46 
environments.  By  these  analyses  it  was  predicted  that  the 
following  residues  (denoted  by  the  single-letter  amino  acid  code 
and  residue  number  starting  from  the  initiating  methionine)  were 
palmitylated:  C99  of A22R,  C36  of A33R,  C19  or C25  of A36R, 
C296  or C301  of A56R,  C301  or C303  of B5R,  and  C185  and/or 
C186  of  F13L.  The  codons  for  these  residues  were  mutated  to 
encode  serine  instead  of  cysteine  by  oligo-directed  mutagenesis. 
In  the  case  of  F13L,  both  cysteine  185  and  186  were  mutated  to 
serine  since  it  has  been  previously  demonstrated  to  be 
palmitylated  on  both  residues  (34).  Also,  since  we  have  observed 
that  the  COP-encoded  A56R  is  palmitylated  but  is  not 
palmitylated  as  expressed  from  the  WR  and  IHO-J  strains,  their 
sequences  were  analyzed  for  differences  occurring  in  the  region 
predicted  to  be  palmitylated.  The  only  difference  noted  was  that 
C301  from  COP  A56R  was  replaced  by  a tyrosine  residue  in  both 
WR  and  IHO-J.  Tyrosine  is  not  known  to  be  an  efficient substrate 
for  palmitylation,  suggesting  that  C301  was  the  palmitate 
acceptor  residue  in  that  protein. 
The  mutated  proteins  were  transiently  expressed  and 
analyzed  by SOS-PAGE  as  above  (Figure  2.5).  The  C99  mutant of 
A22R  still  incorporated  label  as  efficiently  as  the  wild-type 
protein,  perhaps  even  more  efficiently.  The  C36  mutant  of  A33R 
also  incorporated  label  but  at  a  slightly  lower  level  than  the 
wild-type  protein.  This  may  be  due  to  differences  in  expression 
levels  though  and  as  such  C36  may  not  be  the  palmitate  acceptor 
residue.  The  C19  mutant  of  A36R  incorporated  label  as  efficiently 
as  the  wild-type  protein,  while  the  C25  mutant  incorporated  very 
little,  suggesting  that  C25  is  the  primary  palmitate-acceptor 
residue  for  A36R.  The  C301  mutant  of  B5R  incorporated  very  little 
label,  suggesting  that  C301  is  the  primary  palmitate-acceptor 
residue.  The  C303  mutant  of  B5R  incorporated  approximately  half 
that  of  the  wild-type  protein  mutant,  suggesting  possibly  a 
secondary  modification  site.  The  C185/186  mutant  of  F13L  did  not 
incorporate  label  at  detectable  levels  above  background  in 
agreement  with  our  previous  report  (34). 47 
Figure  2.5.  Transient  expression  and  [3H]-PA  labeling  of VV 
candidate  palmitylproteins.  Candidate  palmitylproteins  were 
transiently  expressed  in  BSC40  cells  by  using  the  vTF7-
3/pTM1 :6xHis  system.  Proteins  were  labeled  by  addition  of  [3H]-
PA  to  infected  cells  from  4  to  24  hpi.  Total  cellular  extracts  were 
resolved  on  two  identical  gels  (A  and  B).  One  gel  (A)  was  blotted 
to  nitrocellulose  and  probed  with  Ni+-activated  horseradish 
peroxidase,  which  binds  histidine-tagged  proteins.  The  blot  was 
developed  using  chemiluminescent  reagents  and  exposed  to  film. 
The  other  gel  (B)  was  impregnated  with  PPO  and  exposed  to  film 
to  detect  all  palmitylproteins  in  the  cellular  extracts.  Histidine-
tagged  proteins  were  immunoprecipitated  from  the  same  cellular 
extracts  using  an  anti-6-histidine  monoclonal  antibody. 
Immunoprecipitates were  resolved  by  SDS-PAGE  (C).  The  gel  was 
impregnated  with  PPO  and  exposed  to  film  to  detect 
immunoprecipitated  palmitylproteins.  Gel  lane  assignments  are 
identical  for  all  three  gels  and  are  indicated  above  gel  "A". -- -- --
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2.3.6  [3H]-MA  Labeling of the A 1  4L Protein 
It has  been  previously reported that the A 14L protein is 
myristylated (77). We  attempted to confirm this by transient 
expression of the A 14L protein in  the presence of [3H]-MA, using 
the vTF7 -3/pTM 1  :6xHis system. Although the protein was 
efficiently expressed (Figure 2.6A), it did not incorporate the 
label  (Figure 2.68). We  noticed, though, that overexpression of the 
A 1  4L protein inhibited the production of other late VV 
myristylproteins while the intermediate 14-kOa myristylprotein 
was  still expressed at a low level (Figure 2.68). 
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Figure 2.6. [3H]-MA labeling of the VV A 14L protein. 8SC40 cells 
were infected with vTF7 -3  and  transfected with pTM 1  :A 14L-
6xHis. Cells were labeled by addition of [3H]-MA from 4 to 24 hpi. 
Total cellular extracts were resolved by 50S-PAGE  on  two 
identical gels. One  gel was  blotted to nitrocellulose and  probed 
with Ni+-activated horseradish peroxidase (A). The gel was 
developed by using chemiluminescent reagents and exposed to 
film. The other gel was  impregnated with PPO  and exposed to film 
to detect myristylproteins (8). 50 
2.4  Discussion 
In  identifying  candidate  proteins  for  this  study,  a  number  of 
criteria  were  considered.  First,  we  considered  the  work  of  others 
to  identify  both  viral  and  cellular  palmitylproteins  and  their  sites 
of  modification  (8,  20,  46,  50,  53,  69,  90,  105).  With  this 
information  we  were  able  to  perform  an  alignment  of  numerous 
palmitylproteins  using  the  palmitylated  cysteine  as  a  reference 
point.  In  doing  so,  we  observed  a  loosely  conserved  motif  that 
included  a  hydrophobic  element  that  could  be  a  previously  acylated 
residue  (such  as  a  myristylated  glycine),  a  transmembrane  domain 
or a  hydrophobic  stretch  of  amino  acids.  This  preceded. the 
palmitylated  cysteine  by  a  1- to  12-amino  acid  spacer  region. 
Aliphatic  amino  acids  usually  surround  the  palmitylated  cysteine. 
The  essential  elements  in  this  motif  are  summarized  by  the 
acronym,  Hydro*1-12AACA (34,  35). 
This  motif  by  itself  did  not  allow  the  identification  of  VV 
palmitylproteins.  Therefore,  as  a  second  method  of  identifying  VV 
palmitylproteins,  we  undertook  a  biochemical  characterization  of 
palmitylated  proteins  expressed  in  VV-infected  cells.  We  first 
made  an  effort  to  distinguish  between  VV  myristylproteins  and 
VV  palmitylproteins,  many  of  which  co-migrate  when  resolved  by 
SDS-PAGE.  One  of  our  first  discoveries  was  that  the  ATI  protein, 
which  we  previously  thought  to  be  modified  by  both  myristate  and 
palmitate  (56),  is  in  fact  only  myristylated.  This  was  determined 
by  the  analysis  of  [3H]-MA- or  [3H]-PA-labeled  extracts  from 
cells  infected  with  the  COP,  IHD-J  or  WR  strains  of  vaccinia.  We 
observed  an  86-kDa  palmitylprotein  that  was  expressed  by  COP 
was  absent  from  the  extracts  from  IHD-J- or  WR-infected  cells 
(Figure  2.2).  A  94-kDa  palmitylprotein  was  present  in  the  extracts 
from  all  three  viruses.  In  the  [3H]-MA-labeled  extracts  we 
observed  a 92-kDa  myristylprotein  encoded  by  IHD-J  and  WR  but 
not  COP.  It  is  known  that  the  COP  strain  contains  a  mutation  in  the 
A25L  gene  encoding  the  ATI  protein,  that  results  in  the  premature 51 
termination  of  translation,  producing  a  truncated  peptide  (32,  63). 
Considering,  though,  that  COP  encodes  palmitylproteins  of  86  and 
94  kDa  it  is  likely  that,  due  to  their  similar  migration  rates  in 
SOS-PAGE  gels,  the  94-kDa  palmitylprotein  (also  expressed  by  WR 
and  IHD-J)  and  the  92-kDa  myristylprotein  were  considered  to  be 
the  same.  Our  conclusion  that  the  ATI  protein  is  not  palmitylated 
is  further  supported  by  the  finding  that  with  the  exception  of  L  1  R, 
all  VV  myristylproteins  are  soluble  in  the  cytoplasm  of  infected 
cells  while  all  VV  palmitylproteins  are  found  in  the  particulate 
fraction  of  infected  cells.  A  remote  possibility  exists  that  the 
ATI  protein  is  palmitylated  and  once  it  is  it  becomes  a  component 
of  the  particulate  fraction  of  cells.  This  does  not  seem  likely 
though  because  a  92-kDa  palmitylprotein  present  in  extracts  from 
WR and  IHD-J but not COP  has  not been  observed. 
Also,  in  comparing  the  acylproteins  expressed  by  COP,  IHD-J 
and  WR  strains  of VV,  we  noted  that  COP  encoded  an  86-kDa 
palmitylprotein  whose  migration  pattern  in  SOS-PAGE  gels 
suggested  that  it  was  a  glycoprotein.  We  also  observed  what 
appeared  to  be  the  same  protein  present on  EEV.  It  is  known  that 
the  VV  hemagglutinin  protein  (encoded  by  gene  A56R)  exhibits 
similar  characteristics  so  we  considered  it  a  candidate  for 
palmitylation.  Conceptual  translation  of  the  COP  A56R  gene 
suggested  that  either  C296  or  C301  would  be  possible  palmitate 
acceptor  residues.  C296,  although  surrounded  by  aliphatic 
residues,  is  within  the  predicted  transmembrane  region.  C301  is 
at  the  membrane/cytosolic  boundary  but  is  followed  by  the 
charged  amino  acid,  asparagine.  We  sequenced  the  IHD-J  A56R 
gene and compared  it to  the  WR  and  COP  sequences.  The  amino acid 
sequences  from  the  transmembrane  domain  through  the 
cytoplasmic  tails  for  all  three  proteins  were  identical,  with 
position  301  being  the  exception.  While  COP  had  a cysteine  at 
position  301,  both  IHD-J  and  WR  had  a tyrosine  residue. 
Considering  that we  have  observed  the  COP  hemagglutinin  to  be 
palmitylated  while  the  IHD-J  and  WR  hemagglutinin  are  not,  we 
must  conclude  that  C301  is  the  palmitate  acceptor  residue.  This 52 
conclusion is supported by the work of Payne  (65) in which he 
demonstrated that the IHO-J  hemagglutinin was  not palmitylated. 
Mammalian poxvirus hemagglutinin proteins are  highly 
conserved. All strains of VV and variola have identical sequence 
from the transmembrane domain through the carboxy terminus of 
the protein with the exception of two positions. All strains of VV 
have a threonine at position 288, while all strains of variola have 
an  alanine. The other variable position is  amino acid 301. All 
strains of variola, plus the COP  and  Wyeth strains of VV,  have a 
cysteine !=it  position 301, while VV strains IHD-J,  WR,  LlVP, Tian 
Tan, and MVA have a tyrosine at the same position. The 
significance of the variability at this position is  not clear to us. 
As  part of our biochemical characterization of VV 
acylproteins, we  performed a time-course labeling experiment to 
determine the temporal class to which the VV acyl proteins belong. 
All VV myristyl- and palmitylproteins are expressed primarily at 
late times, suggesting a role in assembly. The one exception is the 
14-kDa acylprotein that incorporated label from both myristic and 
palmitic acids.  We  are  led to conclude that they are the same 
protein due to identical expression characteristics and size. 
Expression of both the myristic and palmitic acid-labeled 14-kOa 
acylprotein began in  the 1- to 2-hpi labeling period, continu.ed 
through the 2- to a-hpi labeling period, and was not detectable in 
the 8- to 24-hpi labeling period. The possibility that both the 
myristylated and  palmitylated proteins are the same  is  supported 
by the fact that a fraction of the label, whether added as  myristic 
or palmitic acid, incorporated by the 14-kOa protein was 
recalcitrant to treatment by neutral hydroxylamine (Figure 2.1 B 
and  2.1 D)  which is  known to cleave thioester-linked moieties such 
as  palmitate (83). This suggests that at least part of the label 
incorporation was  due to the formation of neutral hydroxylamine-
stable amide linkage as  is  typical of myristylation. Vaccinia is 
not predicted to encode a 1  4-kDa protein containing the amino-
terminal myristylation motif MGXXXS/T I A/C/N, and  this 53 
therefore  suggests  that  the  14-kDa  protein  is  the  second  example 
of  VV-encoded  internally  myristylated  protein,  the  first  being  the 
ATI  protein.  It  has  been  previously  reported  that  the  A  14L gene 
encodes  a  14-kDa  myristylprotein  (77).  We  attempted  to  confirm 
this  and  to  determine  whether  this  protein  was  palmitylated  as 
well.  Overexpression  of the  A14L  gene  in  the  presence  of  [3H]-PA 
or  [3H]-MA  did  not  result  in  the  incorporation  of  either  label, 
although  the  protein  was  expressed  at  a  high  level  (Figure  2.5  and 
2.6).  We  did  note,  though,  that  the  high-level  expression  of  A  14L 
inhibited  other  late  protein  production.  The  conclusion  that  the 
A  14L  protein  is  myristylated  was  based  on  a  single  experiment  in 
which  the  A  14L  protein  was  immunoprecipitated  from  myristic 
acid-labeled  infected  cell  extracts.  A  14-kDa  protein  was 
precipitated.  It  may  be  that  the  A  14L  protein  interacts  with  the 
14-kDa  myristylprotein  and  was  thus  co-precipitated,  leading  to 
the  conclusion  that  the  A  14L  protein  was  myristylated.  We  have 
observed  a  similar  phenomenon  when  precipitating  A  14L  from 
palmitic  acid  labeled  infected  cell  extracts.  A  14-kDa 
palmitylprotein  is  co-precipitated  but  migrates  with  a  slightly 
different  migration  pattern  from  A  14L,  allowing  us  to  distinguish 
betwee n  the  two. 
We  have  not  only  identified  novel  palmitylproteins  encoded 
by  the  A22R,  A36R  and  A56R  (COP  strain)  genes  of VV,  but we 
have  been  able  to  accurately  predict  the  palmitate  acceptor 
residue  for  A36R-,  A56R-,  B5R- and  F13L-encoded  proteins. 
Although,  by  our  analyses,  VV  proteins  appear  to  be  palmitylated 
in  a  predictable  manner,  the  misidentification  of  the  A  14L  and 
A34R  proteins  as  candidate  palmitylproteins  and  the  inability  to 
predict  the  modification  sites  on  the  A22R  and  A33R  proteins 
suggest  shortcomings  to  our  system  for  identification  of  VV 
palmitylproteins.  Perhaps  additional  criteria  should  be  considered. 
The  A  14L protein  is  known  to  be  a component  of the  IMV  membrane 
and  the  inner  membrane  of  EEV.  Although  the  primary  amino  acid 
sequence  indicates  that  it  could  be  a  substrate  for  palmitylation, 
its  presence  in  the  IMV  membrane  may  sequester  it  from  the 54 
palmitylation  machinery.  It  is  not  clear  to  us  why  a  protein  in  the 
membrane  of  IMV  would  not  be  palmitylated  while  a  protein  in  the 
membrane  of  EEV  would  be.  Another  factor  that  must  be 
considered  is  membrane  orientation.  The  A36R  protein  is 
predicted  to  be  a type" membrane  protein  and  as  such,  the  most 
likely  palmitate  acceptor  residue  would  be  exposed  to  the  lumenal 
environment  of  intracellular  membrane-bound  compartments  or  to 
the  extracellular  environment  if  it  was  exported  to  the  plasma 
membrane.  These  environments  are  reducing  and  exposure  would 
likely  result  in  the  cleavage  of  the  thioester-bonded  palmitate. 
Our  finding  that  the  A36R  protein  is  palmitylated  on  C25  suggests 
the  opposite  membrane  orientation,  with  a  short  amino-terminal 
lumenal  tail  and  a  long  carboxy-terminal  cytoplasmic  tail.  This  is 
supported  by  a  recent  finding  by  Rottger  et al (82)  that the 
carboxy-terminal  region  of  the  protein  is  cytoplasmic.  Membrane 
orientation  may  explain  why  the  A34R  protein  is  not  palmitylated. 
The  A34R  protein  is  predicted  to  be  a  type  "  transmembrane 
protein  with  a  long,  lumenally  exposed  carboxy-terminal  tail.  The 
predicted  orientation  appears  to  be  correct  based  on  the  findings 
of  Rottger  et al.  Even  though  the  primary  amino  acid  sequence  is 
an  exact  match  for  what  we  define  as  an  optimal  consensus  for 
palmitylation,  the  presence  of· the  motif  in  the  lumenal 
compartment  prevents  palmitylation. 
In  the  report  by  Rottger  et aI,  the  type  II  membrane 
orientation  for  the  A33R  protein  was  confirmed.  Only  one  cysteine 
residue  (C36)  is  present  in  the  cytoplasmic  domain  of  the  protein. 
When  C36  is  changed  to  serine  by  oligo-directed  mutagenesis,  the 
A33R  protein  still  incorporated  [3H]-PA  label,  although  at  slightly 
reduced  efficiency.  Serine  was  chosen  to  replace  cysteine  due  to 
similar  biochemical  characteristics  such  as  size  and  the  polar 
side  chain.  In  retrospect,  this  may  not  have  been  the  best  choice. 
Serine  and  threonine  are  also  substrates  for  palmitylation  but 
only  rarely  (8,  89).  It  may  be  that  replacement  of  a  palmitate-
acceptor  cysteine  with  a  serine  in  an  optimal  environment  results 
in  palmitylation  of  the  serine  residue  through  ester  linkage. 55 
Many  VV  palmitylproteins  are  thought  to  interact  either 
through  disulfide  bonds  or  noncovalently  (65,  82).  The  exact 
nature  of  these  interactions  or  their  biological  significance  is  not 
known.  These  proteins  are  also  involved  in  the  formation  of  lEV, 
the  precursor  of  EEV,  the  propulsion  of  the  lEV  particle  through 
and  out  of  cells  by  actin  polymers,  or  in  the  infectivity  of 
released  virions.  They  are  all  specific  for  the  TGN-enveloped 
virions  and  prior  to  virion  envelopment  are  found  associated  with 
the  membranes  of  the  TGN  (84).  It  is  not  likely  a  coincidence  that 
many  of  these  proteins  are  palmitylated.  It  may  be  that  the 
palmitate  moiety  targets  these  proteins  to  their  respective 
intracellular  location,  i.e.,  the  TGN.  Alternatively,  it  may  be  that 
the  palmitate  moiety  stabilizes  hydrophobic  protein/protein 
interactions.  We  have  previously  reported  that,  at  least  for  the 
F13L  protein  (p37),  the  palmitate  modification  is  necessary  for 
TGN  association  (33,  34)  (see  Chapter  3).  A  mutant  of  p37  that  is 
not  palmitylated  is  soluble  in  the  cytoplasm  of  infected  cells  and 
cannot  function  efficiently  regarding  envelopment  of  IMV.  It  will 
be  of  interest  to  determine  the  biological  significance  of  the 
palmitylation  of  the  other  VV  palmitylproteins. 
VV  continues  to  stand  out  as  an  excellent  system  for  the 
study  of  mammalian  protein  processing.  VV  proteins  (or  exogenous 
proteins  expressed  either  transiently  from  transfected  plasmids 
or  from  recombinant  VV)  are  subject  to  modifications  typical  of 
mammalian  systems,  to  include  sulfation,  phosphorylation,  ADP-
ribosylation,  glycosylation  and,  as  highlighted  here,  acylation.  The 
ease  with  which  VV  is  genetically  manipulated  has  facilitated  the 
study  of  numerous  VV  gene  products,  leading  to  the  identification 
of  three  new  VV  palmitylproteins. 56 
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3.1  Introduction 
Vaccinia  virus  (VV)  is  a  member  of  the  Pox  viridae, a family 
of  large,  complex  DNA  viruses  that  replicate  in  the  cytoplasm  of 
infected  cells  (61).  Its  nearly  200  kilobasepair  genome  has  been 
completely  sequenced  and  appears  to  encode  more  than  200  gene 
products  (32).  While  expressing  many  of the  enzymes  and 
cofactors  required  for  replication  and  expression  of  its  genome, 
including  numerous  nucleotide  metabolizing  enzymes,  the  virus  is 
dependent  on  the  host  cell  translational  machinery  for  protein 
production.  Proteins  are  expressed  in  discrete  temporal  classes, 
starting  with  the  early  class  as  soon  as  15  minutes  after  virus 
entry  into  the  cell.  The  intermediate  class  of  genes  is  expressed 
from  about  2  to  4  h  post-entry,  followed  by  the  late  class,  which 
is  expressed  from  4  h  post-entry  until  cell  death.  Virion  assembly 
coincides  with  late  protein  production. 
The  first  immature  virions  appear  (by  electron  microscopy) 
as  hollow  membrane  crescents  that  loosely  surround  the  core 
components.  The  first  infectious  virions,  referred  to  as  IMV,  are 
formed  as  the  core,  composed  of the  genome,  packaged  enzymes 
and  co-factors,  and  numerous  structural  proteins,  condenses.  The 
envelope  surrounding  the  IMV  particle,  most  likely  derived  from 
the  intermediate  compartment  between  the  endoplasmic  reticulum 
and  the  Golgi  apparatus  (93),  but  possibly  produced  de  novo by 
virus-specific  membrane  forming  machinery,  also  contains  virus-
encoded  proteins  (41).  In  tissue  culture  systems,  IMV  represent 
the  majority  of  virions  produced,  but  the  in  vivo  significance  of 
this  virion  form  remains  to  be  established.  Depending  on  the 
strain  of  virus  and  host  cell,  25-40%  of the  total  IMV  produced  are 
enveloped  with  additional  membranes  and  released  from  the  cell 
(66).  These  multiply  enveloped  forms  of  the  virus  are  likely  of 
greater  significance  in  vivo  as  they  have  been  implicated  in  the 
cell-to-cell  spread  and  long-range  dissemination  of  the  virus 
(67). 58 
The  envelopment  of  IMV  is  a complex  process  that  involves 
targeting  of the  IMV  particle  to  the  TGN,  where,  by  budding 
through  the  compartment,  two  additional  surrounding  membranes 
are  acquired,  forming  lEV  (38).  The  lEV  particle  uses  actin 
polymerization  to  propel  itself  through  and  out  of  the  cell, 
sometimes  into  neighboring  cells  without  exposure  to  the 
extracellular  environment  (10,  17,  37,  39,  96).  At  the  plasma 
membrane,  the  outermost  envelope  of  the  lEV  particle  fuses  with 
the  cell  membrane  releasing  virions  to  the  outside  of  the  cell 
with  the  loss  of the  outermost  membrane.  If  the  virion  remains 
attached  (or  reattaches)  to  the  cell  it  is  referred  to  as  CEV  and 
when  free-floating  in  the  extracellular  medium  it  is  referred  to 
as EEV. 
The  formation  of  infectious  enveloped  virions  is  dependent 
on  numerous  VV-encoded  proteins  including  the  products  of  the 
A27L  (76),  A33R  (80),  A34R  (12,  58,  110),  A36R  (62),  85R  (26, 
109),  and  F13L  (encoding  p37)  (9)  ORFs  of vaccinia.  All  of these 
except  for  the  product  of  A27L,  a  14-kDa  IMV-associated  protein, 
are  specific  for  the  enveloped  forms  of  the  virus  and  are  located 
in  the  outermost envelope  of EEV.  The  A34R  gene  product  is 
glycosylated  (23),  while  the  A33R  and  85R  gene  products  are  both 
glycosylated  and  palmitylated.  The  p37  protein  is  palmitylated  but 
is  not  glycosylated  (65).  The  A36R  protein  has  only  recently  been 
demonstrated  to  be  a  palmitylprotein  (see  Chapter  2)  and  its 
migration  pattern  in  8DS-PAGE  gels  suggests  glycosylation. 
Fatty  acylation  has  been  demonstrated  to  be  an  important 
modification  for  VV-encoded  proteins,  contributing  in  more  than 
one  stage  of  virion  assembly.  In  addition  to  numerous 
myristylproteins  (27),  vaccinia  also  encodes  at  least  eight 
palmitylated  proteins  of  14,  17,  21,  23-28  (a  single  protein),  37, 
42,  45-50  (a  single  protein),  86  (COP  strain  only),  and  94  kDa  (16, 
also  see  Chapter  2).  All  but  the  identities  of the  14- and  17-kDa 
proteins  are  known.  The  21-kDa  protein  is  encoded  by  the  A22R 
ORF.  The  23-28-kDa  protein  (gp23-28)  is  the  glycosylated  product 59 
of the  A33R  gene  previously thought to  be  encoded  by  the  A34R 
gene  (84).  The  37-kDa  protein  is  p37  (40),  the  product  of  the  F13L 
gene  and  the  focus  of  this  chapter.  The  42-kDa  protein  (gp42)  is 
the  glycosylated  product  of  the  85R  gene  (45).  The  45-50-kDa 
protein  (gp45-50)  is  encoded  by  the  A36R  open  reading  frame.  The 
86-kDa  protein  (gp86,  the  VV  hemagglutinin)  is  encoded  by  the 
A56R  ORF of the  COP  strain  of  VV.  The  94-kDa  protein  is  a 
multimeric  complex  composed  of  the  85R  protein  and  possibly 
others.  The  site(s)  of  modification  is  (are)  known  for  gp45-50, 
gp86,  gp42  and  p37. 
p37' is  expressed  from  4  hpi  until  cell  death.  Its 
electrophoretic  mobility  indicates  a  relative  mass  of  37  kDa,  but 
its  predicted  mass,  based  on  amino  acid  content,  is  41  kDa.  Within 
infected  cells,  it  is  targeted  to  the  TGN  (38),  and  when  virion 
associated,  is  specific  for  the  enveloped  forms  of  the  virus  (36, 
64).  Hydrophobicity  and  membrane  topology  predictions  suggest 
that  it  is  a  transmembrane  protein,  based  on  a  hydrophobic  alpha-
helical  region  in  the  central  part  of  the  protein.  Recent 
biochemical  studies  argue  against  the  predictions  and  indicate  the 
protei~  is  a  peripheral  membrane  protein  (91).  The  significance  of 
the  fatty  acyl  moiety  in  anchoring  the  protein  to  membranes  has 
been  demonstrated  by  two  methods.  The  protein  normally 
fractionates  with  the  membranous  components  of  infected  cells 
and  cannot  be  stripped  from  membranes  by  salt  or  carbonate 
extraction.  If  the  membranes  are  treated  with  neutral 
hydroxylamine,  which  cleaves  the  thioester  bonded  palmitate 
moiety  from  the  protein,  the  protein  is  released  from  the 
membranes  (91).  Indirect  immunofluorescent  analysis  of  cells  in 
which  p37  is  transiently  expressed  demonstrates  that  the  wild-
type  protein  is  present  in  discrete  cytoplasmic  foci,  while  a 
nonpalmitylated  mutant  is  evenly  diffused  throughout  the 
cytoplasm  (34). 
Recent  evidence  suggests  that  p37  may  be  a member of the 
phospholipase  D  superfamily,  all  of  which  contain  a  motif 60 
(HXKXXXXD using  the  single-letter amino  acid  code)  also  present in 
p37  (98).  Mutation  of this  motif  in  p37,  or  other  phospholipase  D 
superfamily  members,  results  in  loss  of  function,  either  in  the 
envelopment and  release  of virus  (p37)  or enzymatic  (human  and 
yeast  phospholipase  D).  Baek  et s/ have  demonstrated  that p37 
exhibits  phospholipase  A  and  C  activity  rather  than  phospholipase 
D activity.  The  in  vivo substrates  for  p37  are  unknown.  It  has  been 
suggested  that  the  products  of  the  lipase  reactions  may  be 
involved  in  membrane  fusion. 
While  these  studies  have  contributed  to  our  understanding  of 
p37  function  and  protein-membrane  biochemistry,  they  have  not 
answered  the  fundamental  question,  "Why  is  p37  palmitylated?". 
In  this  chapter  we  have  attempted  to  answer  that  question  by  the 
construction  and  analysis  of  a  mutant  virus  that  expresses  a 
nonpalmitylated  p37  rather  than  the  wild-type  fatty  acylated 
protein.  Our  findings  indicate  that  the  biological  significance  of 
the  acyl  moiety  is  in  targeting  p37  to  intracellular  membranes 
whereby  the  protein  is  functional  in  cooperatively  enveloping  IMV. 
3.2  Materials  and  Methods 
3.2.1  Cells  and  Viruses 
BSC40 and  RK13  cell  lines were  cultured  in  MEM-10  LG/GS 
at 37°C  in  a  5%  C02  humidified  atmosphere.  Upon  infection  with 
VV,  the  cells  were then  cultured  in  Eagle's  MEM  LG/GS  at 37°C  in  a 
5%  C02  humidified  atmosphere.  The  IHD-J  strain  of VV  was 
routinely  propagated  and  titered  in  BSC40  cells  as  previously 
described  (24).  It has  not  been  genetically  altered  and  encodes  the 
wild-type  p37.  The  mutant  virus  vRB10  has  been  previously 
described  (9).  In  vRB10,  93% of the F13L ORF encoding  p37 has 61 
been  deleted  by  insertion  of  the  mycophenolic  acid  resistance 
gene,  gpt,  under  transcriptional  control  by  the  VV  7.S  kDa 
promoter.  It  was  propagated  by  low-multiplicity  passage  through 
BSC40  cells  in  the  presence  of  mycophenolic  acid,  xanthine  and 
hypoxanthine.  Plaque  titrations  were  performed  by  inoculating 
serial  dilutions  of  the  virus  onto  BSC40  monolayers  followed  by 
transfection  of  a  plasmid-borne  rescuing  copy  of  the  F13L  gene 
behind  a  VV  promoter.  Plaques  were  visualized  by  crystal  violet 
staining  at  72  hpi. 
3.2.2  Construction  of  Recombinant  VV 
The  plasmid  pVVS.1 :neo (28)  was  restricted  with  EcoRI  and 
Xbal  to  release  a  1192-basepair fragment  containing  the  entire 
bacterial  neomycin  phosphotransferase  II  (NEO)  gene  (Figure  3.1). 
The  NEO  gene  was  ligated  into  EcoRI-/Nhel-restricted  pRB21  (11), 
placing  the  gene  downstream  from  a  VV  synthetic  early/late 
promoter.  The  resulting  plasmid  is  referred  to  as  pDGS.O.  The 
plasmid  pDG4.3,  previously  demonstrated  to  contain  an  engineered 
mutation  in  the  F13L  ORF  resulting  in  the  expression  of a 
nonpalmitylated  form  of  p37  (34),  was  restricted  with  Spel  and 
Kpnl  to  release  a 672  base  pair  internal  fragment  of the  F13L  ORF. 
This  fragment  was  ligated  into  Spel-/Kpnl-restricted  pDGS.O 
replacing  the  Wild-type  F13L  ORF  with  the  mutated  copy.  This 
plasmid  is  referred  to  as  pDGS.3.  In  this  plasmid,  the  codons  for 
the  normally  palmitylated  cysteines  (cysteines  18S  and  186)  are 
mutated  to  code  for  serine  instead.  The  presence  of the  mutated 
copy  of the  F13L  ORF  was  confirmed  by  restriction  digestion  with 
Hind  III as  there  is  an  additional  site  in  the  mutated  gene  not 
found  in  the  wild-type  sequence  and  by  DNA  sequencing. 
The  plasm ids  were  transfected  into  BSC40  cells 
simultaneously  infected  by  vRB10  as  follows:  Ten  ~g of  plasmid 
DNA  (either pDGS.O  or pDGS.3)  was  added to  1 ml  of MEM  LG/GS  in 62 
Figure  3.1.  Diagram  of  the  construction  of  recombinant  viruses, 
vWTp37  and  vPA-p37.  Plasmids  used  or  constructed  in  this  study: 
pRB21,  pVVS.1 :neo,  pDGS.O,  pDG4.3,  pDGS.3.  Vaccinia promoters 
are  indicated  by  a  boxed  "PH.  Protein-coding  regions  are  indicated 
for each  plasmid.  F13L  encodes  p37,  neo encodes  neomycin 
phosphotransferase  II,  gpt  encodes  hypoxanthine-xanthine  guanine 
phosphoribosyltransferase.  The  nucleotide  sequences  flanking  the 
F13L  open  reading  frame  in  the  vaccinia  genome  are  indicated  by 
F13L+L and  F13L+R.  The  mutated  F13L gene  sequence  and  the 
nonpalmitylated  p37  protein  it  encodes  are  indicated  by  an 
asterisk  (*). 63 
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polystyrene  tubes.  Thirty  III  of  the  liposome  transfection  reagent 
DMRIE-C  (Life  Technologies,  Inc.)  was  added  to  each  tube  followed 
by  incubation  at  room  temperature  for  15  min.  After  the 
DNA:liposome  complexes  had  formed,  1x1 06  infectious  units  of 
vRB10  were  added  to  the  mixture.  The  virus/DNAlliposome 
mixture  was  inoculated  onto  1x1 06  BSC40  cells  in  35-mm  wells 
of  a  6-well  tissue  culture  plate  and  incubated  for  48  h  at  37°C  in 
a  5%  C02  humidified  atmosphere.  At  48  hpi  the  infected  cells 
were  washed  free  of  the  tissue  culture  plate  and  suspended  in  the 
culture  medium.  Cells  were  pelleted  from  the  suspension  by 
centrifugation  at  700  x  g,  4°C,  for  10  min.  The  cells  were 
resuspended  in  100  III  PBS  and  frozen,  then  thawed,  3  times  to 
lyse  cells  and  release  virus.  Ten  III  of  the  infected  cell  Iysates 
was  used  as  an  inoculum  to  infect  1x107  BSC40  cells  on  100-mm 
plates  that  had  been  pretreated  with  G418  at  a  concentration  of 
200  Ilg/ml  in  the  culture  medium  for  24  h  before  infection.  Upon 
infection,  theG418  concentration  was  increased  to  400  Ilg/ml  in 
the  culture  medium  (MEM  LG/GS).  The  infection  continued  for  48  h 
at 37°C  in  a 5%  C02  humidified  atmosphere.  The  cells  were  then 
scraped  free  from  the  plate  and  resuspended  in  the  culture 
medium.  The  cells  were  pelleted  from  the  culture  medium  by 
centrifugation  at  700  x  g,  4°C,  for  10  min.  The  cells  were 
resuspended  in  1 ml  of  PBS  and  frozen,  then  thawed,  3 times  to 
lyse  cells  and  release  virus.  One  hundred  III  of  the  infected  cell 
Iysates  was  used  as  an  inoculum  to  infect  BSC40  cells.  The 
process  of  passing  virus  through  G418-pretreated  BSC40  cells  in 
the  presence  of  G418  was  repeated  3  times  to  enrich  for 
recombinant  viruses  expressing  NED. 
After  the  third  passage  to  enrich  for  recombinants, 
individual  virions  were  amplified  to  obtain  pure  virus  stocks.  This 
was  accomplished  by  two  separate  techniques.  The  recombinant 
virus  expressing  the  wild-type  p37,  code  named  vWTp37,  was 
purified  by  screening  virus  stocks  grown  from  individual  plaques 
formed  in  BSC40  monolayers  overlaid  with  agar-containing 
medium  plus  200  Ilg/ml  G418.  The  expression  of  p37  by  this  virus 65 
was  confirmed  as  described  below.  The  recombinant  virus 
expressing  the  mutated  and  presumably  nonpalmitylated  form  of 
p37,  code  named  vPA-p37,  did  not  form  normal-sized  plaques  (see 
Results  below)  so  it  could  not  be  plaque  purified  as  described  for 
vWTp37.  Instead,  individual  viruses  were  cultured  by  inoculating 
serial  dilutions  of  the  G418-passaged  stocks  onto  BSC40  cells  in 
96-well  tissue  culture  plates  and  treating  with  200  J.1g/ml  G418 
in  the  culture  medium  as  generally  outlined  by  Blasco  and  Moss 
(9).  At  72  hpi  each  well  was  examined  microscopically  to 
determine  if  microplaques  were  forming.  Wells  that  had  no 
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plaques  or  more  than  one  microplaque  were  disregarded.  The  cells 
from  individual  wells  with  only  one  detectable  microplaque  were 
scraped  free  from  the  plate  with  a  pipette  tip,  resuspended  in  the 
culture  supernatant,  transferred  to  microcentrifuge  tubes,  and 
frozen,  then  thawed,  3  times.  The  entire  cell  lysate  was  used  as 
an  inoculum  to  infect  1x106  BSC40  cells  in  6-well  tissue  culture 
plates.  The  cells  were  pretreated  with  200  J.1g/ml  G418  for  24  h 
before  infection  and  the  infection  was  carried  out  in  the  presence 
of  200  J.1g/ml  G418.  At  24  hpi  the  cells  were  harvested  and 
Iysates  prepared  by. freeze-thaw  as  described  above.  The  Iysates 
were  screened  for  p37  production  as  described  below  and  only 
those  Iysates  that  contained  p37  were  purified  further.  The  p37-
containing  cell  Iysates  were  serially  diluted  and  inoculated  onto 
BSC40  cells  in  96-well  plates  that  had  been  pretreated  with 
G418.  Individual  microplaques  were  observed  microscopically  at 
72  hpi,  harvested  and  amplified  in  the  presence  of  200  J.1g/ml  of 
G418  as  above.  The  limiting  dilution  purification  of  vPA-p37  was 
performed  a  total  of  3  times.  Purified  stocks  of  vWTp37  and  vPA-
p37  were  prepared  as  previously  described  (24)  and  stored  at 
-70°C. 66 
3.2.3  Sodium  Dodecylsulfate-Polyacrylamide  Gel 
Electrophoresis  (SDS-PAGE)  and  Immunoblot  Detection 
of  Proteins 
Proteins  from  cell  Iysates  or  from  purified  virion  samples 
were  boiled  in  reducing  sample  buffer  and  resolved  by 
discontinuous  gel  electrophoresis  as  described  by  Laemmli  (52). 
All  gels  used  were  12.50/0  polyacrylamide:bis-acrylamide  (30:0.8). 
The  proteins  were  transferred  from  gels  to  nitrocellulose  (99)  and 
sequentially  probed  with  antibodies  directed  against  VV  antigens 
followed  by  enzyme-conjugated  secondary  antibodies.  The  blots 
were  developed  by  addition  of  chemiluminescent  substrates  and 
exposure  to  film.  All  primary  antibodies  were  from  polyclonal 
antiserum  produced  in  rabbits  and  have  been  described  previously. 
Polyclonal  antiserum  directed  against  p37  (a-p37)  (91)  was  used 
at  1:10,000  while  antibodies  directed  against  the  25-kDa  VV  core 
protein  (a-25K)  (108)  and  the  IMV  membrane  protein  encoded  by 
the  L  1  R ORF  (a-L1R)  (29)  were  used  at 1:1000.  The  secondary 
antibody  was  a  goat-anti-rabbit  IgG  polyclonal  conjugated  to 
horseradish  peroxidase  (GaR-HRP)  diluted  1  :40,000  for  use.  The 
antibody:protein  complexes  were  detected  by  incubating  the  blots 
with  SuperSignal® chemiluminescent  substrate  solutions  (Pierce) 
followed  by  exposure  to  BioMax™  MR-2  film  (Kodak). 
3.2.4 [3H]-Palmitic  Acid 	Labeling  of  Virion  Proteins  and 
Immunoprecipitation  of  p37 
BSC40  cells  were  grown  to  confluence  (106  cells)  in  35-mm 
wells  of  6-well  tissue  culture  plates.  The  cells  were  infected 
with  IHD-J,  vRB10,  vWTp37  or  vPA-p37 at a moi  of 10.  At 4 hpi 
the  media  were  aspirated  and  replaced  with  MEM  LG/GS  containing 
200  J.1Cilml  [3H]-PA.  The  infections  continued  until  24  hpi  at  37°C 
in  a 50/0  C02  humidified  atmosphere.  The  cells  were  suspended  in 67 
the  culture  medium  by  repeatedly  pipetting  it  over  the  cell 
monolayer.  The  cell  suspensions  were  subjected  to  centrifugation 
at  12,000 x  g,  4°C  for  30  min  to  pellet  cells  and  virus  particles. 
The  pellets  were  resuspended  in  100  III  of  PBS  and  frozen,  th~n 
thawed,  3  times.  Twenty  III  was  boiled  in  reducing  SOS-PAGE 
sample  buffer,  and  then  equally  divided  between  two  12.5% 
polyacrylamide  gels.  Following  electrophoresis,  one  gel  was 
impregnated with  PPO:OMSO,  dried and  exposed  to  BioMax™  MR-2 
film  at  -70°C  (13).  The  other  gel  was  transferred  to 
nitrocellulose  and  p37  was  detected  by  antibodies  and 
chemiluminescence  as  above.  The  remaining  80  III  of  infected  cell 
Iysates  was  diluted  to  580  III  in  2X  strength  RIPA  buffer  and 
incubated  on  ice  for  15  min.  The  solutions  were  then  diluted  to  1  X 
concentration  with  water.  One  III  of  a-p37 was  added  to  each 
sample  followed  by  incubation  on  ice  for  2  h.  Then,  40  III  of a 50% 
slurry  of  protein  A-sepharose  beads  in  1X  RIPA  was  added  and 
incubation  was  continued  for  18  h  at  4°C  with  constant  agitation. 
The  immunoprecipitated  proteins  were  washed  three  times  with 
1  X  RIPA,  transferred  to  a  new  microcentrifuge  tube  and  washed 
again.  The  beads  were  pelleted  a final  time  and  resuspended  in 
reducing  sample  buffer  and  heated  to  70°C  for  1 min.  The  proteins 
were  resolved  by  SOS-PAGE  using  12.5%  polyacrylamide  gels  as 
above.  Following  electrophoresis  the  gels  were  fluorographed  by 
impregnation  with  PPO:OMSO,  drying  and  exposure  to  BioMax™  MR-
2  film  at  -70°C. 
3.2.5 Plaque  Formation  and  Infectious  Titer  Assays 
Serial  dilutions  of  purified  virion  preparations  or  infected 
cell  Iysates  were  made  in  MEM  LG/GS  and  inoculated  onto 
confluent  monolayers  of  BSC40  cells  in  35-mm  wells  of  6-well 
tissue  culture  plates.  Under  duplicate  infection  conditions  one  set 
of  cells  inoculated  with  vRB10  or  vPA-p37  dilutions  was 
simultaneously  transfected  with  pRB21  (a  plasmid  encoding  wild-68 
type  p37)  to  enhance  plaque  formation  and  facilitate 
determination  of  infectious  titer  for  these  samples.  At  48  hpi,  the 
cell  monolayers  were  stained  with  0.1 %  (w/v)  crystal  violet  in 
30%  (v/v)  ethanol  and  plaques  observed  both  macro- and 
microscopically. 
3.2.6  Metabolic  Labeling  and  Purification  of  Virions 
RK13  cells  (1 x1 07)  were  seeded  onto  150-mm  tissue  culture 
plates and  cultured  in  MEM-10  LG/GS  at 37°C  in  a 50/0  C02 
humidified  atmosphere  for  24  h.  The  cells  were  infected  with 
either  IHD-J,  vRB10,  vWTp37  or  vPA-p37  at  moi  of 10  and 
cultured  in  MEM  LG/GS  until  4 hpi  at 37°C  in  a 50/0  C02  humidified 
atmosphere.  The  culture  media  were  aspirated  and  replaced  with 
methionine-deficient  minimal  essential  medium  containing  22.0 
IlCi/ml  [35S]-methionine/cysteine  and  LG/GS.  The  infection 
continued  until  24  hpi.  The  culture  supernatants  were  transferred 
to  15-ml  tubes  and  centrifuged  at  700  x  g,  4°C  for  15  min  to 
pellet  free-floating  cells.  The  supernatants  were  transferred  to 
centrifuge  tubes  and  subjected  to  ultracentrifugation  at  100,000 
x g,  4°C  for  1 h.  The  pellets were  resuspended  in  1 ml  of PBS  and 
plaque-assayed  to  determine  infectious  titers  as  described  above. 
Purification  of  virus  from  the  infected  RK13  cell  Iysates  by 
sucrose  gradients  was  as  previously  described  (42).  The  cell 
monolayers  were  washed  with  PBS  and  then  resuspended  in  10  mM 
Tris-CI  pH  8.0.  The  cells  were  allowed  to  swell  on  ice  for  15  min 
then  Dounce  homogenized  to  lyse  them  and  release  virus.  The 
cellular  debris  was  pelleted  by  centrifugation  at  700  x  g,  4°C  for 
15  min.  The  virus-containing  supernatants  were  layered  onto  6  ml 
36%  sucrose  cushions  and  subjected  to  ultracentrifugation  at 
55,000  x  g,  4°C  for  80  min.  The  pellets were  resuspended  in  1  ml 
of  10  mM  Tris-CI  pH  8.0  and  Duall  homogenized  to  disrupt 
aggregated  material.  They  were  then  layered  onto  25-40%  sucrose 69 
gradients  and  subjected  to  ultracentrifugation  at  33,000  x  g,  4°C 
for  40  min.  The  virus  bands were  side-pulled  by  using  a  needle  and 
syringe  to  withdraw  the  entire  band  in  no  more  than  1  ml  of 
solution.  Each  virus  sample  was  diluted  to  1  ml  with  water  and 
plaque-assayed  to  determine  infectious  titers  as  described  above. 
The  remaining  samples  of  extracellular  and  cell-associated 
virus  were  further  purified  by  CsCI  gradients  (68).  The  gradients 
were  prepared  in  ultracentrifuge  tubes  by  first  adding  5ml of  a 
1.2  g/ml  CsCI  solution,  followed  by  under-laying  through  Pasteur 
pipettes  4  ml  of  a  1.25  g/ml  Cs  CI  solution,  then  2.5  ml  of  a  1.3 
g/ml  CsCI  solution.  The  virus  samples  were  subjected  to 
ultracentrifugation  at  100,000  x  g,  15°C  for  2  h.  Five  hundred-Ill 
fractions  were  collected  from  the  bottom  of  the  gradients  and  the 
radioactivity  per  fraction  was  measured  by  scintillation  counting. 
Peak  fractions  for  IMV  and  EEV  (as  determined  by  relative  position 
in  the  gradient)  were  pooled,  diluted  in  water  to  12  ml  and 
subjected  to  ultracentrifugation  at  100,000  x  g,  4°C  for  1 h.  The 
virus  pellets  were  resuspended  in  100  III  of  PBS  and  quantitated 
again  by  scintillation  counting. 
3.2.7 Proteinase  K Treatment  of  Purified  IMV  and  EEV 
EEV  and  IMV  samples,  containing  equivalent  radioactivity, 
were  treated  with  proteinase  K  at  a  final  concentration  of  2 
1l9/ml  in  PBS  for  1  h  at  room  temperature  (91).  Duplicate 
reactions  were  mock-treated.  All  reactions  were  stopped  by 
addition  of  reducing  SDS-PAGE  sample  buffer  and  boiling  for  three 
min.  Samples were  resolved  by  SDS-PAGE  (12.5%)  and  blotted  to 
nitrocellulose.  The  blots  were  probed  with  a-p37, and  a-25K  then 
stripped  and  probed  with  a-L1R.  Chemiluminescent  detection  of 
proteins  was  as  described  above. 70 
3.2.8  Electron  Microscopy  (EM) 
BSC40  cells  (1x107)  in  100-mm  tissue  culture  plates  were 
infected  with  either  IHD-J,  vRB10,  vWTp37  or  vPA-p37  at  moi  of 
10.  At  16  hpi  the  cells  were  scraped  free  from  the  plates  and 
resuspended  in  the  culture  medium.  The  cells  were  pelleted  by 
centrifugation  at  700  x  g,  4°C  for  10  min.  The  cells  were  washed 
in  PBS  and  pelleted  again  by  centrifugation.  The  cells  were  fixed 
by  resuspension  in  2.S%  paraformaldehyde  (w/v):  200  mM 
cacodylate  buffer,  pH  7.4,  and  incubating  at  4°C  for  8  h.  The  cells 
were  pelleted  by  centrifugation  and  washed  once  with  200  mM 
cacodylate  buffer,  pH  7.4.  The  cells  were  left  in  200  mM 
cacodylate  buffer  pH  7.4  at  4°C  for  16  h.  The  cells  were  pelleted 
by  centrifugation.  The  cacodylate  buffer  was  aspirated  and 
replaced  with  a  1%  osmium  tetroxide (wlv)  solution.  The  cell 
pellet  was  then  incubated  at  room  temperature  for  1  h.  The 
samples  were  dehydrated  by  sequential  1S-min  incubations  in 
2S%,  So%,  7So /0  and  100% acetone.  The  100% acetone  incubation 
was  repeated  three  times.  The  samples  were  then  infiltrated  with 
Spurr's  plastic.  The  samples  were  incubated  at  room  temperature 
in  solutions  of  1/3  Spurr's:2/3  acetone  for  4  h  followed  by  2/3 
Spurr's:1/3  acetone  for  16  h and  finally  100%  Spurr's  for  6  h.  The 
samples  were  placed  under vacuum  and  heated  to  70°C  for  16  h. 
Sectioning  was  performed  by  personnel  of  the  Oregon  State 
University  EM  laboratory  on  a  Sorvall  Porter-Blum  model  MT2 
ultramicrotome.  Sections  were  post-stained  by  using  Reynold's 
lead  citrate  and  uranyl  acetate  before  examination  by 
transmission  EM. 71 
3.2.9  Indirect  Immunofluorescent  and  Fluorescent 
Microscopy 
BSC40  cells  were  seeded  onto  microscope  slide  cover  slips 
("microcover  glasses",  VWR)  at  a  density  of  5x105  cells  per  35-
mm  well  in  6-well  tissue  culture  plates  and  cultured  24  h  at  37°C 
in  a  5%  C02  humidified  atmosphere.  The  cells  were  infected  with 
either  IHO-J,  vRB10,  vWTp37  or  vPA-p37  at moi  of 10.  At  8 hpi 
the  cells  were  rinsed  with  ice-cold  PBS  followed  by  100% 
methanol.  The  cells  were  prepared  for  immunofluorescent 
microscopy  as  described  by  Watkins  (107).  The  cells  were  fixed  by 
incubating  in  3.7%  formalin  for  20  min  at  room  temperature 
followed  by  permeabilization  with  0.2%  Triton  X100.  The  cells 
were  rinsed  twice  for  5  min  with  ice-cold  PBS.  The  cells  were 
incubated  with  the  primary  antibodies  a-p37 (used  at  a  1  :2000 
dilution)  or a-L1  R (used  at  a  1  :500  dilution)  in  PBS  containing  2% 
bovine  serum  albumin  (BSA)  as  a blocking  agent,  for  1 h at 4°C. 
The  cells  were  rinsed  four  times  for  5  min  each  with  ice-cold 
PBS.  The  secondary antibody was  a  goat-anti-rabbit  IgG 
tetramethylrhodamine  isothiocyanate  conjugate  (GaR-TRITC; 
Sigma)  used  at a 1  :64  dilution  in  PBS  containing  2%  BSA.  The 
secondary  antibody  incubations  were  for  1  h at  4°C  in  the  dark. 
Forty  min  into  the  secondary  antibody  incubation,  fluorescein 
isothiocyanate-conjugated  phalloidin  (Sigma)  was  added  to  a  final 
concentration  of  1  Jlg/ml.  Twenty  min  later,  the  secondary 
antibody  solution  was  aspirated  and  the  cells  washed  four  times 
for  5  min  with  ice-cold  PBS.  The  final  wash  was  aspirated  and  the 
cells  allowed  to  air-dry  for  10  min  before  mounting  on  slides  and 
examination  by  confocal  fluorescent  microscopy. 72 
3.2.10  Subcellular  Fractionation 
BSC40 cells  were  grown  to  be  95%  confluent  in  150-mm 
tissue  culture  plates  (2x101  cells).  The  cells  were  infected  with 
either  IHD-J,  vRB10,  vWTp37,  or  vPA-p37  at  moi  of 10.  The 
infected cells  were  cultured  in  MEM  LG/GS  at 37°C  in  a  5%  C02 
humidified  atmosphere  for  16  h.  The  culture  media  were 
transferred  to  ultracentrifuge  tubes  and  clarified  by  a  100,000  x 
g,  4°C,  1  h  centrifugation.  The  cells  were  washed  free  of the 
plates  with  10  ml  of  ice  cold  PBS.  The  cells  were  pelleted  by 
centrifugation  at 700  x  g,  4°C  for  10  min.  The  cells  were 
fractionated  using  differential  centrifugation  essentially  as 
described  by  Child  and  Hruby  (16).  The  PBS  was  aspirated  and the 
cells  resuspended  in  1.2  ml  of hypotonic  buffer  (HB,  20  mM  HEPES 
pH  7.6,  5 mM  potassium  chloride,  1 mM  magnesium  chloride,  150 
mM  sodium  chloride)  and  incubated  10  min  on  ice  to  swell  the 
cells.  All  subsequent  steps  were  at  4°C.  The  cells  were  then  lysed 
by  Dounce  homogenization.  Two  hundred  JlI  of  each  cell  lysate  was 
set  aside  as  the  total  cell  extracts  (TCE)  while  the  remainder  was 
subjected  to  centrifugation  at  700  x g  for  10  min.  The 
supernatants  (post-nuclear  supernatant,  PNS)  were  transferred  to 
new  microcentrifuge  tubes  for  further  fractionation  while  the 
pellets  from  that  centrifugation  were  resuspended  in  1.0  ml  of  HB 
and  set aside  as  the  nuclear  pellet  (NP).  The  PNS  were  transferred 
to  centrifuge  tubes  and  diluted  to  4.5  ml  with  HB  and  subjected  to 
ultracentrifugation  at  100,000  x  g  for  60  min.  The  pellets  from 
this  centrifugation  (P100)  were  resuspended  in  1  ml  of  HB  and  set 
aside  as  the  particulate  cytoplasmic  fractions.  The  supernatants 
from  this  centrifugation  and  the  clarified  culture  supernatants 
were  adjusted  to  10%  trichloracetic  acid  and  subjected  to 
centrifugation  at  15,000  x g for  30  min.  The  pellets  from  this 
centrifugation  were  set  aside  as  the  soluble  cytoplasmic 
fractions  (S100)  and  the  soluble  culture  supernatant  fractions 
(SUP).  All  other  fractions  were  adjusted  to  be  100/0  trichloracetic 
acid  and  subjected  to  centrifugation  at  15,000  x  g  for  30  min. 73 
With  the  exception  of the  TCE  fractions,  which  were  resuspended 
in  20  JlI,  all  precipitated  pellets  were  resuspended  in  100  JlI  of  1 
M  Tris,  pH  10  to  neutralize  the  acid  and  briefly  sonicated  to 
facilitate  resuspension.  Twenty  JlI  of  each  fraction  was  analyzed 
by  SOS-PAGE  (12.5%  polyacrylamide  gel)  and  immunoblot  using  a-
p37  as  the  primary  antibody.  For  chemiluminescent  detection,  the 
primary  antibody  incubation  was  followed  by  incubation  with 
GaR-HRP,  then  SuperSignal® chemiluminescent  substrate 
solutions  followed  by  exposure  to  BioMax™  MR-2  film.  Relative 
quantitation  of  protein:antibody  complexes  was  performed  by  film 
densitometry. 
3.3  Results 
We  have  previously  demonstrated  that  p37  is  palmitylated 
on  cysteine  residues  185  and  186  of  the  372  amino  acid  protein 
(34,  also  see  Chapter  2).  In  addition  we,  along  with  others  (91), 
have  confirmed  that  it  is  the  fatty  acyl  modification,  and  not  the 
predict~d transmembrane  domain  consisting  of  a  hydrophobic 
alpha-helical  region  in  the  middle  of  the  protein,  that  mediates 
membrane  interaction  by  p37.  These  studies  have  been  performed 
either  in  vitro  or  by  transient  expression  of  p37.  To  understand 
the  biological  significance  of  the  fatty  acyl  modification  in  an  in 
vivo  context,  we  sought  to  construct  a  recombinant  VV  expressing 
a  nonpalmitylated  p37  rather  than  the  wild-type  fatty  acylated 
protein.  Once  the  recombinant  was  constructed,  we  then 
performed  a  series  of  assays  designed  to  compare  its  activity  to 
that  of  the  wild-type  virus,  IHO-J.  p37  is  known  to  be  involved  in 
the  process  of  envelopment  and  release  of  virions  (9),  so  we 
tested  for  plaque  formation  (a  process  dependent  on  enveloped 
virions),  release  of  virions  from  infected  cells  and  retention  of 
enveloped  virions  within  infected  cells.  Also,  the  nucleation  of 
actin  to  propel  virions  through  and  out  of  the  cell  is  abrogated  in 
the  absence  of  p37  (17).  It  is  not  clear  whether  p37  is  directly 74 
involved  in  actin  nucleation  or  merely  a  player  in  a  prerequisite 
reaction.  For  that  reason,  we  examined  cells  by  fluorescent 
microscopy  after  fluorescently  labeling  VV  antigens  and  F-actin. 
Also,  to  confirm  our  previous  studies,  we  analyzed  infected  cells 
and  virions  for  p37  localization  to  determine  whether  the 
palmitate  moiety  was  important  in  targeting  p37  to  virions  or 
intracellular  membranes. 
3.3.1  Construction  of  Recombinant  Viruses 
To  facilitate  the  construction  of  the  recombinants  used  in 
this  study,  two  plasm ids  were  made  (Figure  3.1).  One  encodes  the 
wild-type  p37  (pOG5.0)  and  the  other  contains  a  mutated  F13L 
sequence  demonstrated  to  encode  a  nonpalmitylated  p37  (pOG5.3) 
by  transient  expression  (34).  The  plasmid  pOG5.3  contains 
mutations  that  result  in  the  replacement  of  the  normally 
palmitylated  cysteines  (cysteines  185  and  186)  with  serines.  The 
F13L  ORF  on  both  plasm ids  is  transcriptionally  regulated  by  the 
native  F13L  promoter  and  is  flanked  by  sequences  neighboring  the 
F13L  locus  in  the  VV  genome  to  allow  for  homologous 
recombination  into  its  native  site.  The  neo  gene  mediating  G418 
resistance,  behind  a  synthetic  VV  early/late  promoter,  is  also 
present -on  the  plasm ids  to  allow  for  selection  of  recombinants. 
Cells  were  infected  with  vRB10,  a  virus  that  does  not 
produce  p37  due  to  an  F13L  deletion,  and  transfected  with  either 
pOG5.0  or pOG5.3.  The  progeny were  passed  numerous times  in  the 
presence  of  G418  followed  by  a  plaque-purification  of  the  wild-
type  p37-encoding  virus,  termed  vWTp37,  or  a  limiting  dilution 
purification  of  the  nonpalmitylated  p37-encoding  virus,  termed 
vPA-p37.  The  viruses  were  tested  for  expression  and 
palmitylation  of  p37  by  labeling  infected  cells  with  [3H]-PA 
followed  by  immunoprecipitation  of  p37  from  the  cell  extracts. 
The  immunoprecipitates  were  resolved  by  SOS-PAGE  and 75 
Figure  3.2.  Expression  and  palmitylation  of  p37.  The  tritiated 
palmitic  acid-labeled  extracts  from  cells  infected  with  virus  as 
indicated  above  the  gel  lanes  in  panel  A were  analyzed  for  p37 
expression  by  immunoblot  (A)  using  anti-p37  antiserum  and 
chemiluminescent  development  of  the  blot.  p37  was  analyzed  for 
incorporation  of  the  labeled  palmitic  acid  by  immunoprecipitation 
(8),  resolution  by  SOS-PAGE,  and  fluorography.  The  efficiency  of 
labeled  palmitate  incorporation  by  other  vaccinia  proteins  was 
demonstrated  by  SOS-PAGE  and  fluorography  of  the  total  infected 
cell  extracts  (C).  Molecular  weights  are  indicated  beside  each  gel 
or  blot.  The  previously  described  vaccinia  palmitylproteins  are 
indicated  to  the  right  of  panel  C.  Unknown  palmitylproteins  are 
indicated  by  a  "?".  The  46-kOa  and  28-kOa  forms  of  p37  described 
in  the  text  are  indicated  by  enclosing  p37  in  parentheses  (p37). C 
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fluorographed  to  detect  label.  The  tritium  label  was  incorporated 
by  p37  expressed  from  IHD-J  or vWTp37  (Figure  3.2B)  but was  not 
incorporated  at  detectable  !evels  by  vPA-p37-expressed  p37 
although  the  immunoblotsof the  same  cell  extracts  demonstrate 
that  it  was  expressed  at comparable  levels  (Figure  3.2A).  We  also 
noted  that  when  total  [3H]-PA-labeled  infected  cell  extracts  were 
resolved  by  SDS-PAGE  and  fluorographed,  there  were  three  labeled 
protein  bands  in  the  extracts  from  IHD-J  and  vWTp37  that  were 
absent from  vRB10  and  vPA-p37  (Figure  3.2C).  The  same  three 
bands  were  recognized  by  a-p37  in  immunoblots  suggesting  that 
they  all  represent  some  form  of p37.  The  37  kDa  band  was  the 
predominant  form  of  the  protein  while  the  46-kDa  and  28-kDa 
forms  are  present  in  reduced  amounts.  We  have  concluded  that 
both  vWTp37  and  vPA-p37  express  p37  at  levels  comparable  to 
IHD-J  and  that vPA-p37  encodes  a  nonpalmitylated  p37. 
Furthermore,  p37  is  present  in  at  least  two  additional  forms  other 
than  the  well-characterized  37-kDa  form,  although  the  faster 
migrating  species  may  represent  a  degradation  product,  as  we 
discuss  below. 
3.3.2  Formation  of  Enveloped  Virions  by  vPA-p37 
The  formation  of  lEV,  and  subsequently  CEV  and  EEV,  is 
dependent on  p37  (9).  The  mutant virus  vRB10  has  had  the  F13L 
ORF  insertionally  inactivated  and  93%  deleted  by  a  gpt expression 
cassette  mediating  mycophenolic  acid  resistance.  As  a  result,  it 
is  inefficient  at  producing  either  enveloped  virions  or  plaques  on 
cell  monolayers,  for  cell-to-cell  spread  is  dependent  on  enveloped 
virions.  The  virus  still  produces  normal  amounts  of  infectious 
IMV,  which  are  retained  intracellularly  unless  released  by  cell 
lysis.  Therefore,  the  ability  to  form  plaques  on  cell  monolayers 
stands  as  a  simple  test  for  enveloped  virus  production  and 
release. 78 
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Figure 3.3. Plaque  formation by wild-type and  recombinant 
viruses. Monolayers of cells were infected at a low multiplicity of 
infection to allow observation of individual plaques. At 48 hours 
post-infection, the liquid overlay was  aspirated and  the cells 
stained with crystal violet. The infecting virus is  indicated above 
the macroscopic view. Magnification is  indicated to the left of 
both the macro- and  microscopic views. 
BSC40  cell  monolayers were infected with serial dilutions 
of either IHO-J,  vRBl 0, vWTp37 or vPA-p37 and cultured for 48 h. 
The cell monolayers were then stained with crystal violet to 
enhance visualization of the plaques. Both IHO-J  and  vWTp37 
formed characteristic plaques with tails making them comet-like 
in  appearance (Figure 3.3). This plaque morphology is  the result of 
a single amino acid change in  the A34R protein (12) and  is  typical 
of IHD-J  and  its derivative strains or mutants. Both vRB 10 and 
vPA- p37 did not form visible plaques within 48 h although very 
small plaques were visible to the naked eye between 72 and  96 
hpi. As  confirmation that we  had  infected with vRBl 0 and  vPA-
p37, the cell monolayers were inspected microscopically. We  were 79 
able  to  see  microplaques  forming  at  48  hpi  but  they  were  only 
approximately  1/10  the  size  of  IHD-J  or  vWTp37  plaques  (Figure 
3.3). 
To  assure  ourselves  that  inefficient  enveloped  virus 
production  was  a bona  fide  vPA-p37  phenotype  we  used  another 
system  to  assay  enveloped  virus  production.  It  has  been 
demonstrated  that  the  amino  acid  substitution  on  the  A34R 
protein  leading  to  the  production  of  comet-like  plaques  is  also 
responsible  for  the  enhanced  release  of  EEV  from  RK13  cells  (66). 
RK13  cells  were  infected  with  either  IHD-J,  vRB10,  vWTp37  or 
vPA-p37  at  moi  of  10  and  cultured  until  24  hpi.  The  virus  purified 
from  the  culture  supernatant,  which  at 24  hpi  is  almost  100
%  EEV, 
and  the  virus  purified  from  cell  extracts  were  separately  tested 
for  infectious  titer  by  plaque  assay.  To  enhance  plaque  formation 
by  vRB10  and  vPA-p37,  cells  were  simultaneously  transfected 
with  pRB21,  a  plasmid  that  transiently  expresses  p37  in  VV-
infected  cells.  All  viruses  produced  roughly  equivalent  amounts  of 
cell-associated  virus  (predominantly  IMV).  While  there  was  a 
nearly  1:1  ratio  of  cell-associated  virus  to  extracellular  virus  for 
IHD-J,  vRB10  produced  approximately  60- to  70-fold  less 
extracellular  virus  (Figure  3.4).  The  1:1  ratio  is  restored  for 
vWTp37  as  expected  since  the  wild-type  F13L  gene  has  been 
reinserted  into  the  vRB10  genome.  vPA-p37  remained  defective 
for  release  of  virus,  producing  from  33  to  more  than  100  times 
more  cell-associated  virus  than  extracellular  virus. 
Both  envelopment assays  employed  above  are  dependent on 
the  production  and  release  of  infectious virus.  Mutants  of VV  have 
been  described  that  release  normal  amounts  of  EEV  but  with  very 
low  infectivity,  resulting  in  a  small-plaque  phenotype  (58).  We 
considered  this  a  possibility  for  vPA-p37,  making  necessary  the 
quantitation  of  virion  particles  produced.  RK13  cells  were 
infected  as  above  and  labeled  with  r 35S]-methionine/cysteine 
after  4  hpi.  At  24  hpi  virions  were  concentrated  from  the  culture 
medium  and  purified  from  cell  Iysates  as  described  in  Materials 80 
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Figure  3.4.  Comparison  of  virus  production  and  release.  RK13  cells 
were  infected  with  virus  as  indicated  on  the  "X"  axis.  At  24  hours 
post-infection  virus  was  purified  from  cell  Iysates  (cell-
associated  virus)  and  the  culture  supernatants  (extracellular 
virus)  and  plaque  titrated  to  determine  infectious  virus 
production.  The  ratio  of  cell-associated  to  extracellular  virus  is 
given  above  the  bars  for  each  virus. 
and  Methods.  The  labeled  virus  particles  were  purified  by 
centrifugation  in  esCI  gradients  that  were  then  fractionated, 
followed  by  determination  of  radioactivity  per  gradient  fraction. 
IMV  is  separable  from  enveloped  virions  due  to  differing  buoyant 
densities  (68).  While  a"  viruses  produced  roughly  equivalent 
amounts  of  IMV  as  determined  by  radioactive  peaks  in  the  gradient 
at 1.26 to  1.27 g/ml  (Figure  3.58),  IHO-J  and  vWTp37  had 
significantly  higher  peaks  of  radioactivity  in  fractions 
corresponding  to  densities  at  which  enveloped  virions  sediment 81 
Figure 3.5. Quantitation of IMV and  EEV  by metabolic labeling and 
CsCI  gradient purification. Virus from cells  (B) or the culture 
media (A) of RK13 cells,  infected and  labeled as  outlined in 
Materials and  Methods, was  separated according to density by CsCI 
gradient centrifugation. Fractions were collected from the bottom 
of the gradients and radioactivity per fraction was  quantitated by 
scintillation counting. 82 
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(1.22-1.24  g/ml).  Detection  of  enveloped  virions  above  background 
was  possible  in  vRB10-or  vPA-p37-infected  cells,  and  both 
released  a  small  amount  of  virus  into  the  culture  medium  with 
buoyant  densities  characteristic  of  EEV  (Figure  3.5A)  but  in  both 
cases  they  were  drastically  reduced  from  the  normal  levels.  A 
small  amount  of  IMV  was  detectable  in  the  culture  media  of  all 
viruses  at  24  hpi  and  was  probably  due  to  cell  lysis. 
These  experiments  indicate  that  vPA-p37  is  defective  in  the 
production  and  release  of  enveloped  virions.  vPA-p37  does  not 
display  an  intermediate  phenotype,  suggesting  that  palmitylation 
is  absolutely  necessary  for  p37  function  regarding  envelopment 
and  release  of  virions. 
3.3.3  EM  Examination  of  vPA-p37-lnfected  Cells 
The  morphogenesis  of  VV  has  been  extensively  characterized 
by  transmission  EM  (21,  43,  79,  93,  94).  The  production  of  IMV 
occurs  in  discrete  perinuclear  foci  termed  viroplasm,  virosomes 
or  virus  factories.  At  approximately  4  hpi  the  first  membrane 
crescents  appear  in  the  virus  factories  and  are  most  likely 
derived  from  the  membranes  of  the  intermediate  compartment  or 
vesicles  from  it.  The  membrane  crescents  become  closed  circles 
as  the  core  components  are  loosely  packaged  within.  Then  the  core 
condenses  to  the  characteristic  bi-concave  or  "dumbbell"  shape 
and  the  virion  acquires  a  brick-like  shape.  At  this  time  it  is 
possible  to  see  by  EM  that the  virion  is  wrapped  by  a  single 
membrane.  The  IMV  particle  is  then  targeted  to  the  membranes  of 
the  TGN.  Upon  budding  through  the  compartment,  two  additional 
membranes  are  acquired,  forming  lEV.  The  formation  of  lEV  is 
dependent  upon  p37  as  well  as  numerous  other  VV-encoded 
proteins.  Since  vPA-p37  appears  defective  for  the  production  and 
release  or  enveloped  virions,  we  examined  infected  cells  by 84 
transmission  EM  to  determine  the  stage  at which  envelopment  was 
arrested. 
BSC40  cells  were  infected  with  virus  at  a  moi  of  10.  At  16 
hpi  the  cells  were  treated  as  outlined  in  Materials  and  Methods  to 
prepare  them  for  transmission  EM.  Upon  comparing  IHD-J  and 
vRB10,  two  differences  were  noted:  1)  While  IHD-J  virions  had 
disseminated  throughout  the  cell  to  the  periphery  (see  vWTp37), 
vRB10  virions  remained  concentrated  in  perinuclear  clusters 
distinct  from,  but  near  the  virus  factories  (Figure  3.6).  2)  At 
higher  magnification  it  was  not  difficult  to  detect  IHD-J  virions 
in  association  with  intracellular  membranes,  in  the  process  of 
being  enveloped  by  them,  and  fully  enveloped  as  lEV,  but  all  vRB10 
virions  had  a  distinct  IMV  morphology.  As  expected,  vWTp37  was 
indistinguishable  from  IHD-J  at  high  and  low  magnifications  due 
to  restoration  of  the  wild-type  F13L  to  the  vRB10  genome.  Within 
vPA-p37-infected  cells,  only  IMV  could  be  observed,  and  like 
vRB10,  most  virions  were  concentrated  in  perinuclear  clusters.  It 
seems  then,  that  palmitylated  p37  is  necessary  not  only  for 
envelopment  of  IMV  to  form  lEV,  but  also  for  movement  away  from 
the  perinuclear  location  of  virion  production. 
3.3.4 Fluorescent  Microscopic  Analysis  of  the 	Actin  Stress 
Network  and  Localization  of  VV  Antigens 
Vaccinia  uses  actin  polymerization  for  intracellular 
motility  and  projection  outside  the  cell,  presumably  into 
neighboring  uninfected  cells.  This  is  observed  by  fluorescent 
microscopy  as  a  reorganization  of  the  cellular  actin  stress 
network  to  form  thick  actin  tails  up  to  0.74  IlM  in  length  that  are 
tipped  with  a  single  lEV  particle  (18).  Drugs  or  mutations  that 
block  the  production  of  lEV  also  prevent  the  nucleation  of  actin 
tails  (17)  so  we  would  expect  vPA-p37  to  be  defective  for  this 
process.  Additionally,  by  transient  expression  of  a 85 
Figure  3.6.  Electron  microscopy  of  infected  cells.  Thin  sections  of 
BSC40  cells  infected  with  virus  as  indicated  above  the  electron 
micrographs  were  examined  by  transmission  electron  microscopy. 
Note  virion  clusters  in  vRB10- and  vPA-p37-infected  cells 
(16,400X  magnification)  while  vWTp37  virions  are  well 
disseminated  throughout  the  cell.  Note  also  envelopment  of 
vWTp37  virions  by  intracellular  membranes  (73,000X 
magnification).  Original  magnification  is  indicated  to  the  left  of 
the  micrographs. 86 
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nonpalmitylated  p37  within  infected  cells,  we  have  demonstrated 
using  immunofluorescent  microscopy  and  subcellular 
fractionation  that  the  mutated  protein  is  at  least  partially 
soluble  (34).  Transient  expression  results  in  the  overexpression  of 
the  protein  in  some  cells  while  in  others  it  is  not  expressed. 
Altered  expression  levels  may  have  resulted  in  discrepancies 
between  the  wild-type  protein  and  the  mutant  regarding 
localization.  As  an  extension  of  our  previous  work,  we  repeated 
our  assays  for  p37  localization  using  the  recombinant  viruses 
vWTp37  and  vPA-p37,  which  express  p37  at  levels 
indistinguishable  from  the  wild-type  IHO-J. 
BSC40  cells  were  infected  with  virus  at  a  moi  of 10  for  8  h. 
The  cells  were  fixed  and  stained  with  polyclonal  sera  to  p37  and 
L  1  R,  an  IMV  membrane-associated  protein,  and  fluorescent 
secondary  antibodies.  F-actin  was  stained  by  using  fluorescein-
labeled  phalloidin.  Confocal  fluorescent  microscopy  was  used  to 
observe  localization  of  VV  antigens  and  polymerized  actin.  Mock-
infected  cells  had  very  little  background  fluorescence  specific  for 
the  VV  antigens  while  maintaining  an  intact  actin  cytoskeleton 
(Figure  3.7).  At  8 hpi,  both  IHO-J  and  vWTp37  had  completely 
reorganized  the  actin  cytoskeleton.  Numerous  thick  actin  tails 
were  visible  and  appeared  to  be  tipped  with  virions  based  on  p37 
and  L  1  R  localization.  Since  it  is  known  that  when  virion-
associated,  p37  is  specific  for  the  enveloped  forms  of  the  virus 
(lEV,  CEV  and  EEV),  it  is  likely that these  represent  lEV. The  IMV 
outer  membrane  protein,  L  1  R  is  somewhat  concentrated  in  the 
perinuclear  region  of  IHO-J- and  vWTp37-infected  cells,  but  is 
also  distributed  throughout  the  cytoplasm  in  a  slightly  punctate 
pattern.  On  the  other  hand,  p37  is  distinctly  punctate  throughout 
the  cytoplasm  of  IHO-J- and  vWTp37-infected  cells  as  would  be 
expected  for  a  TGN-associated  protein.  Within  vRB10-infected 
cells  the  actin  cytoskeleton  has  been  broken  down  but  not 
reorganized  into  the  thick  filaments  typical  of  the  wild-type 
virus.  Based  on  the  localization  of  L  1  R,  which  is  concentrated  near 
the  nucleus  with  little  staining  in  the  cytoplasm,  virions  appear 88 
Figure  3.7.  Immunofluorescent  microscopy  of  infected  cells.  The 
localization  of  VV  antigens,  p37  and  L  1  R,  and  F-actin  were 
determined  by  indirect  fluorescent  labeling  and  confocal 
microscopy.  The  fluorescently  labeled  antigens  are  indicated  at 
the  top  of  each  column  and  the  infecting  viruses  are  indicated  to 
the  left  of  each  row.  All  images  were  captured  through  a  100X 
magnification  oil  immersion  objective.  Images  of  F-actin  staining 
were  zoomed  1.5X.  Thick  actin-containing  microfilaments  are 
indicated  by  arrows. 89 
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to  have  remained  near the  nucleus,  in  agreement with  our EM 
observations.  As  expected,  p37-specific  fluorescence  was  not 
above  background  due  to  the  deletion  of  F13L  from  vRB10.  In 
agreement  with  our  previous  findings,  p37  was  distributed 
diffusely  throughout  the  cytoplasm  of  vPA-p37-infected  cells,  as 
would  be  expected  for  a  soluble  protein,  while  L  1  R-specific 
staining  was  concentrated  near  the  nucleus,  as  was  observed  for 
vRB10.  Like  vRB10,  the  actin  cytoskeleton  was  disassembled  but 
not  reorganized  in  vPA-p37-infected  cells. 
3.3.5 Subcellular  Fractionation  of  VV-Infected  Cells 
As  we  have  discussed  previously,  the  membrane  interaction 
of  p37  is  mediated  by  the  palmitate  moiety.  This  was  first 
demonstrated  by  Schmutz  et a/ (91)  and  confirmed  by  site-
directed  mutagenesis  and  transient  expression  analysis  of  a 
nonpalmitylated  p37  (34).  Within  infected  cells,  p37  is  targeted 
to  the  membranes  of  the  TGN  and  co-localizes  with  other  EEV-
specific  antigens  (84).  If  cellular  membrane  fractions  containing 
p37  are  treated  with  neutral  hydroxylamine,  cleaving  palmitate 
from  p37,  then  p37  becomes  soluble.  By  indirect 
immunofluorescence  and  differential  centrifugation  subcellular 
fractionation,  transiently  expressed  nonpalmitylated  p37  behaves 
as  a  soluble  protein  and  does  not  co-localize  with  other  EEV-
specific  proteins  as  efficiently  as  the  wild-type  protein.  We 
sought  to  confirm  and  extend  these  findings. 
BSC40  cells  were  infected  with  virus  at a  moi  of  10  for  16 
h.  The  infected  cells  were  then  fractionated  by  differential 
centrifugation  to  yield  a  nuclear  fraction  (NP)  and  a  cytoplasmic 
fraction  (PNS)  that  was  further  fractionated  to  yield  a  particulate 
cytoplasmic  fraction  (P100)  and  a  soluble  cytoplasmic  fraction 
(S100).  In  addition,  the  culture  media  (SUP)  were  clarified  by  a 
100,000  x  g  centrifugation,  concentrated  by  addition  of 91 
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Figure  3.8. Subcellular fractionation of infected cells.  Infected 
cells (as indicated above the topmost gel) were fractionated by 
differential centrifugation to yield a total cell extract (TCE),  a 
nuclear fraction (NP), a particulate cytoplasmic fraction (P1 00) 
and  a soluble cytoplasmic fraction (S 100). The culture 
supernatants (SUP)  along with the subcellular fractions were 
assayed for p37 by SOS-PAGE  and  immunoblots developed by 
chemiluminescence. Relative amounts of p37 were determined by 
film densitometry and the percent of the total 
(NP+Pl OO+S 1OO+SUP)  for each virus are given below the gel of 
each fraction. Note the increased percentage of p37 in  the S100 
and  SUP  fractions of vPA- p37. 
trichloracetic acid and assayed along with the other fractions for 
p37 by SOS-PAGE  and immunoblot. Following chemiluminescent 
development of the blots, the relative protein concentrations 
were obtained by film densitometry. While vPA- p37 expressed p37 
at similar levels as  IHO-J  and vWTp37 as  determined by 
comparison of the total cell extracts (TCE), it was  depleted from 
both the NP and Pl 00 (Figure 3.8). The majority of vPA- p37-92 
expressed  p37  was  found  in  the  S100  and  SUP  fractions  while  very 
little  IHO-J- or  vWTp37-expressed  p37  was  found  in  the  soluble 
fractions.  This  confirms  our  previous  finding  of  increased 
solubility  for  p37  when  not  palmitylated. 
3.3.6 Analysis  of  Virion-Associated  p37 
Schmutz  et a/ (91)  have  demonstrated  that  p37  decorates 
the  cytoplasmic  face  of  the  TGN  and  after  virion  envelopment  is 
situated  on  the  core-proximal  face  of  the  outermost  envelope  of 
EEV.  It  may  be  that p37  is  EEV  associated  only  by  default due  to 
TGN  association  but  this  is  unlikely  considering  that  p37  is 
necessary  for  envelopment  of  virus.  A  TGN-associated  receptor 
for  the  IMV  particle  has  not  been  identified,  but  seems  likely  to 
exist,  as  the  IMV  particle  is  specifically  wrapped  by  TGN 
membranes.  We  considered  the  possibility  that  p37  is  the  TGN 
receptor  for  IMV  and  that  it  is  not  found  to  be  IMV  associated  due 
to  strong  TGN  interaction  distal  from  the  site  of  IMV  production. 
EEV  and  IMV  were  purified  from  cultures  of  metabolically 
labeled  RK13  cells  infected  with  either  IHO-J,  vRB10,  vWTp37  or 
vPA-p37.  Equivalent  amounts  of  EEV  and  equivalent amounts  of 
IMV,  as  determined  by  radioactive  counts  per  sample,  were 
resolved  by  SOS-PAGE,  blotted  to  nitrocellulose  and  probed  with 
antibodies  to  p37,  L  1  R and  the  25-kOa  core  protein  followed  by 
secondary  antibody  incubations  and  chemiluminescent 
development  (Figure  3.98).  As  expected,  p37  was  found  to  be 
specific for  EEV  produced  by  IHO-J  and  vWTp37.  We  also  found  p37 
to  be  vPA-p37  EEV  associated,  but  in  relatively  smaller  amounts 
than  that  found  on  viruses  encoding  the  wild-type  p37. 
Surprisingly,  vPA-p37-produced  p37  was  also  IMV  associated, 
leading  us  to  believe  that  it was  the  IMV  receptor  on  the  TGN.  We 
also  observed  the  L  1  R and  the  25-kOA  core  protein  to  be  both  IMV 
and  EEV  associated  as  has  been  previously  shown  (71,  102).  If p37 93 
Figure  3.9.  Analysis  of  virion-associated  p37.  Virus  (as  indicated 
above  each  gel  lane)  was  purified,  by  CsCI  gradients,  from  the 
culture  medium  of  infected  RK13  cells.  (A)  Resolution  of  EEV 
polypeptides  by  SOS-PAGE  and  autoradiography.  Arrow  indicates 
position  of  p37  in  IHO-J  and  vWTp37  lanes.  (8)  Proteinase  K 
treatment  of  purified  EEV  and  IMV.  Mock-treated  or  proteinase  K-
treated  (as  outlined  in  Materials  and  Methods)  EEV  and  IMV  were 
resolved  by  SOS-PAGE  and  blotted  to  nitrocellulose.  The  blots 
were  sequentially  probed  for  p37  and  25K  then  L  1  R,  which  are 
indicated  to  the  left  of  each  gel.  Note  the  presence  of  undigested 
p37  in  the  proteinase  K-treated  IMV  sample. 94 
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is  the  TGN-associated  ligand  for  IMV,  then  if  soluble  it  should 
decorate  the  outside  of  IMV.  To  test  this,  equivalent  amounts  of 
EEV  and  equivalent  amounts  of  IMV  were  treated  with  2  f.1g/ml 
proteinase  K  (PK)  for  1 h at  room  temperature  to  degrade  any 
exposed  proteins.  Following  PK  treatment  the  reactions  were 
stopped  by  addition  of  SOS-PAGE  sample  buffer  and  boiling  for  3 
min.  The  reaction  mixtures  were  treated  as  above  to  detect  p37, 
L  1  R and  the  25-kDa  core  protein.  The  25-kDa  core  protein  was  PK-
resistant  on  both  IMV  and  EEV  while  L  1  R was  PK-sensitive  on  both 
IMV  and  EEV.  The  vPA-p37  EEV-associated  p37  was  PK-sensitive 
while  a  portion  of  the  IMV-associated  p37  was  PK-resistant.  This 
suggests  that  p37  most  likely  is  not  exposed  on  the  outer  face  of 
vPA-p37  IMV  but  that  it  is  protected  within  the  core  of  the 
particle.  Two  major  p37-derived  degradation  products  were 
recognized  by  the  p37  polyclonal  antiserum.  The  larger  fragment, 
of  approximately  29  kOa,  co-migrates  with  one  of  the  three  bands 
detectable  by  a-p37  in  total  cell  extracts  suggesting  that  some 
p37  is  degraded  by  cellular  or  viral  proteases  in  a  manner  similar 
to  PK  proteolysis.  The  smaller  proteolytic  product  is  detectable 
by a-p37 as  a diffuse  band  running  between  11  to  14 kOa. 
3.4  Discussion 
Palmitylation  of  p37  was  first  observed  by  Hiller  and  Weber 
(38).  Since  then  the  protein  has  been  characterized  extensively 
both  biochemically  and  biologically.  It  is  palmitylated  and/or 
oleated  (34,  65)  on  cysteines  185  and  186  of  the  372-amino  acid 
polypeptide.  The  fatty  acyl  modification  serves  as  a  membrane 
anchor,  for  without  it  the  protein  is  soluble  (34,  91).  Within 
infected  cells,  p37  is  targeted  to  the  TGN  (84)  where  it  plays  an 
important  role  in  the  envelopment  and  release  of  virions  (9).  The 
mutant virus,  vRB10  does  not  express  p37  and  as  a consequence 
produces  very  little  lEV,  CEV  or  EEV  while  producing  normal 
amounts  of  IMV.  Normally,  VV  reorganizes  the  actin  cytoskeleton 96 
using  actin  polymerization  for  intercellular  and  perhaps 
intracellular  movement  (17).  Possibly  because  lEV  are  not  formed, 
virus-tipped  thick  actin  filaments  are  not  found  in  vRB10-
infected  cells. 
Recent  findings  suggest  that  p37  is  a  member  of the 
phospholipase  D superfamily  based  on  the  presence  of a conserved 
motif  (98).  The  HXKXXXXD  motif  (using  the  single  letter amino  acid 
code)  and  an  additional  conserved  serine  are  only  partially 
conserved  in  p37,  but  mutagenesis  of  any  of  the  conserved 
residues  results  in  a  loss  of  function  for  the  protein.  These 
findings  all  indicate  an  important  role  for  p37  in  the  late  stages 
of  the  VV  life  cycle  but  do  not  entirely  disclose  the  significance 
of  the  palmitate  modification. 
In  this  report  we  have  described  the  construction  and 
characterization  of  a  VV  mutant  that  expresses  a  nonpalmitylated 
p37  rather  than  the  wild-type  fatty  acylated  form.  Because  the 
known  role  of  p37  is  to  mediate  (along  with  other  VV  proteins) 
the  envelopment  of  IMV,  our  assays  were  designed  to  examine  that 
aspect  of  VV  biology.  In  most  assays,  the  nonpalmitylated  p37 
mutant  virus  (vPA-p37)  is  indistinguishable  from  the  F13L 
deletion  mutant  vRB10,  suggesting  that  the  fatty  acyl  moiety  is 
indispensable  for  protein  function. 
Most  often  the  purpose  of  palmitylation  is  membrane 
targeting  and  anchoring  of  proteins,  but  occasionally  it  serves 
another  purpose  (47,  54,  60).  We  considered  the  possibilities  that 
palmitylation  of  p37  regulated  protein-protein  interactions  or 
that  the  protein  cycled  between  an  inactive  nonpalmitylated  pool 
and  an  active  palmitylated  pool  as  a  means  of  regulating  protein 
function.  It  has  not  been  conclusively  demonstrated  that  p37  has 
any  protein  partners  although  it  is  known  to  co-localize  with 
numerous  VV  proteins  in  infected  cells  (84).  With  what  is  known 
about  p37  we  can  only  conclude  that  palmitylation  does  not  serve 
as  a  mediator  of  protein-protein  interactions.  Likewise, 97 
palmitylation  does  not  appear  to  serve  as  a  regulatory  mechanism 
for  p37  function.  As  we  have  demonstrated  by  both  subcellular 
fractionation  and  immunofluorescent  microscopy,  nearly  100
%  of 
the  wild-type  p37  is  a  component  of  the  particulate  fraction  of 
cells,  suggesting  efficient  membrane  interaction.  We  have  also 
demonstrated  the  protein-membrane  interaction  to  be  dependent 
on  palmitylation  as  well  as  being  necessary  for  p37  function.  If 
palmitylation  served  as  a  regulatory  function  we  would  expect  a 
significant  fraction  of  the  protein  to  be  nonpalmitylated.  Instead, 
we  find  that  less  than  1%  of  the  protein  is  not  palmitylated  (34). 
It  seems  that  the  sole  purpose  of  p37  palmitylation  is  to  target 
and  anchor the  protein  in  the  membranes  of  the  trans-Golgi 
network.  By  our  analyses  presented  here  it  is  apparent  that  p37 
interaction  with  the  TGN  is  absolutely  necessary  for  function. 
In  their  analysis  of  p37,  Baek  et a/  purified  bacterially 
expressed  p37  and  tested  it  for  lipase  activity,  which  they  found. 
We  have  not  observed  palmitylation  of  p37  in  bacterial  cells.  This 
suggests  that  palmitylation  is  not  necessary  for  enzymatic 
activity  and  that  the  defect  in  the  nonpalmitylated  p37  is  solely 
targeting.  Considering  our  findings  along  with  the  findings  of  Baek 
et a/ and  Sung  et aI,  it  appears  that  the  lipase  activity  of  p37  is 
required  for  the  formation  of  lEV  and  that  it  must  be  specifically 
localized  to  the  TGN  for  its  activity  to  be  biologically  relevant. 
The  in  vivo  substrates  for  this  enzyme  are  unknown. 
In  summary,  we  have  demonstrated  palmitylation  of  p37  to 
be  necessary for targeting  p37  to  the  membranes  of the  TGN.  The 
association  of  p37  with  the  TGN  membranes  is  an  absolute 
requirement  for  the  function  of  p37.  The  primary  biological 
activity  of  p37  is  best  demonstrated  by  the  F13L  deletion  mutant 
vRB10,  which  is  deficient  for  all  aspects  of  envelopment  and 
release  of  virus,  while  producing  normal  amount  of  IMV.  When  the 
wild-type  F13L  sequence  is  restored  to  the  vRB10  genome,  the 
mutant  is  rescued.  But  when  the  mutated  F13L  sequence,  encoding 
a  nonpalmitylated  p37,  is  inserted  into  vRB10,  the  resulting 98 
recombinant  virus  is  indistinguishable  from  vRB10  in  the  assays 
described  here.  The  lack  of  an  intermediate  phenotype  suggests  a 
complete  loss  of  function  for  the  protein. 
Vaccinia  virus  continues  to  stand  out  as  a  uniquely  capable 
model  system  for  the  analysis  of  mammalian  protein  processing. 
Besides  acylation,  VV  polypeptides  are  subject  to  proteolytic 
processing,  glycosylation,  phosphorylation,  ADP-ribosylation, 
disulfide  cross-linking  (103)  and  sulfation  (65).  We  have  yet  to 
decipher  all  the  intricacies  of  these  modifications  in  VV  or 
eukaryotic  systems  and  palmitylation  of  proteins  is  one  of  the 
least  understood  of  these  processes.  Perhaps  exploitation  of  the 
VV  system  will  allow  us  to  examine  not  only  various  functions  of 
protein  palmitylation  but  to  identify  factors  mediating  the 
process,  including  those  responsible  for  the  modification  reaction 
and  molecular  properties  of  the  modified  protein. 99 
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4.1  Significance  of  the  Research 
The  value  of  this  work  may  be  appreciated  from  two 
separate  perspectives:  as  it  relates  to  vaccinia  virus  biology,  and 
to  palmitylation  of  proteins  in  general.  The  series  of  events 
leading  to  the  production  of  infectious  virions  from  VV-infected 
cells  is  complex  and  understood  only  at  the  macromolecular  level. 
The  specific  role  of  individual  proteins  is  often  unknown.  By  our 
study  of  protein  palmitylation  in  VV-infected  cells  we  have 
contributed  to  the  understanding  of  intracellular  and  virion 
targeting  of  proteins  as  well  as  the  process  of  virion  envelopment 
and  release.  Palmitylation  of  proteins  itself  is  not  well 
understood.  Although  many  palmitylproteins  have  been  identified, 
as  have  their  sites  of  modification,  it  has,  to  this  point,  been 
difficult  to  predict  which  proteins  are  palmitylated  and  on  which 
residues.  Through  our  efforts  we  have  been  able  to  predict  not 
only  which  VV  proteins  are  palmitylated,  but  also  their  sites  of 
modification. 
Research  on  VV  continues  to  be  significant for a  number of 
reasons.  First,  VV  itself  is  a  pathogenic  virus,  closely  related  to 
smallpox.  Although  smallpox  has  been  eradicated  it  has  not  been 
destroyed.  In  addition  to  the  small  amount  of  virus  reserved  for 
research  purposes,  the  possibility  exists  that  it  may  be  (or  has 
been)  mass  produced  as  a biological weapon.  Research  on  VV 
biology  provides  insight  for  the  treatment  of  smallpox  should  an 
outbreak occur.  Second,  VV  is  also  used  as  a vaccine  and  a 
transient  gene  therapy  vector.  Recombinant  DNA  technology  has 
allowed  the  development  of  VV  beyond  its  traditional  use  as  an 
anti-smallpox  vaccine.  To  ensure  the  efficacy  and  safety  of  the 
vaccines/vectors,  virulence  mechanisms  and  the  means  to 
attenuate  them  must  be  understood.  Third,  VV  is  widely  used  as  a 
transient  expression  vector.  One  of  the  reasons  for  its  popularity 
is  that  proteins  expressed  by  recombinant  VV  are  processed  as 
they  would  be  in  their  native  systems.  The  disadvantage  to  using 101 
VV  for  transient  expression  is  that  the  virus  is  cytopathic, 
resulting  in  cell  death  soon  after  infection.  Research  on  VV  must 
continue  if  its  potential  as  a  transient  expression  vector  is  to  be 
realized 
By  our  work  we  have  demonstrated  that  palmitylation  alone 
is  sufficient  to  target  a  protein  (p37)  to  its  proper  intracellular 
membrane-bound  compartment.  The  loss  of  the  targeting  signal  on 
p37  is  debilitating  for  the  virus  resulting  in  an  attenuated 
phenotype  in  tissue  culture  systems.  This  in  itself  highlights  that 
the  virus,  as  a  result  of  its  complexity,  is  dependent  on  numerous 
cellular processes.  Anyone of these  processes  may  serve  as  a 
target  for  inhibiting  virus  replication.  This  is  not  to  suggest  that 
palmitylation  of  VV  proteins  would  serve  as  an  appropriate  target 
for  anti-viral  therapeutics.  In  fact,  the  opposite  is  most  likely 
true.  Inhibition  of  protein  palmitylation  would  likely  be  lethal  for 
most  cells,  not  just  the  virus.  Since  VV  is  easily  manipulated  at 
the  genetic  level,  it  would  be  possible  though,  using  the  research 
presented  here,  to  construct  recombinant/mutant  viruses 
engineered  to  be  deficient  for  certain  processes  and  thus  generate 
attenuated  vaccines/vectors. 
Palmitylation  of  proteins  occurs  in  numerous  if  not  all 
mammalian  cell  types.  Many  mammalian  viruses  encode  at  least 
one  palmitylprotein  as  well.  The  significance  of  the  modific"ation 
is  not  always  understood.  The  use  of  VV  has  allowed  access  to 
numerous  palmitylproteins  in  an  easily  manipulated  system.  The 
ability  to  work  with  these  proteins  in  a  limited  environment 
permitted  the  definition  of  a  small  number  of  biochemical 
characteristics  that  specify  palmitylation  of  proteins.  Extending 
from  the  work  of  others,  analyzing  substrates  for  palmitylation  in 
other  systems,  we  were  able  to  define  a  primary  structural  motif 
in  proteins  specifying  palmitylation.  The  motif  is  defined  here  as 
Hydro*1-12AACA, where  "Hydro*"  represents  a  hydrophobic 
element  followed  by  a  1- t012-amino  acid  spacer.  The  spacer 
region  precedes  the  palmitylated  cysteine  (C),  which  is  often 102 
surrounded  by  aliphatic  (A)  amino  acids.  Analysis  of  VV  proteins 
for  this  motif  led  to  the  identification  of  seven  of  the  nine  VV-
encoded  palmitylproteins  (if  the  COP  strain  hemagglutinin  protein 
is  counted).  The  sites  of  modification  for  five  of  the  seven  known 
palmitylproteins  were  accurately  predicted  simply  by  analysis  of 
cysteine  residues  that  fell  within  the  motif. 
The  ramifications  of  this  work  extend  beyond  VV  biology.  As 
stated  before,  VV  proteins  are  subject  to  numerous  modifications 
typical  of  mammalian  cell  proteins  and  are  processed  in  an 
authentic  manner.  The  use  of  VV  as  a model  system  should  allow  a 
greater  understanding  of  cellular  palmitylproteins. 
4.2  Suggestions  for  Future  Research 
VV-encoded  palmitylproteins  are  all  specific  for  the  TGN-
enveloped  forms  of  the  virus.  Many  of these  proteins  have  been 
demonstrated  to  be  involved  either  in  the  envelopment  and 
dissemination  of  enveloped  virions  or  in  the  infectivity  of 
released  enveloped  virions.  It  will  be  of  interest  to  determine  the 
role,  if  any,  of  the  A22R  protein  in  the  process  of  envelopment  and 
release.  Mutant  viruses  should  be  constructed  which  either  do  not 
express  A22R  or  repress  its  expression  unless  induced.  These 
viruses  could  then  be  compared  to  wild-type  viruses  in  the  same 
assays  employed  to  characterize  the  nonpalmitylated  p37  mutant 
vPA-p37.  The  newly  discovered  VV-encoded  palmitylproteins,  as 
well  as  the  previously  known  but  uncharacterized  VV 
palmitylproteins,  A22R,  A33R,  A36R,  A56R  and  85R,  offer  the 
unique  opportunity  to  study  biological  function  of  palmitylation  on 
numerous  proteins  in  a  single,  easily  manipulated  system.  Most  of 
these  proteins  are  transmembrane  proteins,  so  the  function  of  the 
palmitate  moiety  is  not  so  easily  predicted.  For  some 
transmembrane  proteins,  palmitylation  is  dispensable  for  function 
while  on  others  it  is  absolutely  necessary. 103 
It  is  not  clear  why  the  hemagglutinin  protein  (A56R)  from 
the  COP  strain  of  VV  would  be  palmitylated  while  the  same 
protein,  expressed  from  the  WR  and  IHD-J  strains,  is  not.  The 
ability  of  these  viruses  to  agglutinate  red  blood  cells  should  be 
compared.  Then,  perhaps,  viruses  should  be  constructed  which 
express  the  hemagglutinin  from  another  strain  and  its  virulence 
compared  to  the  wild-type  virus.  All  strains  of  variola  (smallpox) 
as  well  as  monkeypox  contain  a  cysteine  residue  in  the 
homologous  position  as  the  palmitylated  cysteine  in  the  COP 
hemagglutinin.  It  is  possible  that  palmitylation  of  the 
hemagglutinin  is  a  virulence  factor  for  these  viruses.  Although  it 
is  not  possible  to  work  with  smallpox,  the  ability  to  exchange 
these  different  genes  between  strains  of  VV  should  answer  a  few 
of  the  questions  about  the  role  of  the  palmitate  moiety  on  the 
hemagglutinin. 
The  14- and  17-kDa  palmitylproteins  are  still  unidentified. 
Our  inability  to  predict  which  ORFs  encode  these  proteins  only 
highlight  that  our  palmitylation  motif  is  not  perfect.  More  work 
must  be  done  to  determine  what  additional  criteria  should  be 
included  in  screening  for  palmitylproteins.  Factors  that  should  be 
considered  are;  subcellular  localization  of  the  modification 
reaction,  temporal  regulation  of  the  reaction,  membrane 
orientation  of  the  target  protein,  identification  of  enzymes  or 
factors  required  for  the  reaction,  and  refinement  of  the  primary 
structural  motif. 
Perhaps  the  most  interesting  work  that  needs  to  be 
performed  is  the  determination  of  function  for  all  of  these 
proteins.  The  process  of VV  envelopment  not only  serves  as  a 
model  system  for  protein:protein  interaction  and 
protein:membrane  biochemistry,  but  is  an  important  aspect  of  VV 
virulence.  If  VV  is  to  be  further  developed  as  a  vectorivaccine,  its 
virulence  mechanisms  must  be  understood.  An  understanding  of 
the  role  that  these  proteins  play  in  the  VV  life  cycle  will  likely 
provide  numerous  targets  for  attenuating  the  virus.  To  date,  there 104 
is  no  convincing  evidence  for  protein:protein  interaction  by  any  of 
these  proteins.  Yet,  these  proteins  all  co-localize  within  infected 
cells,  and  are  all  involved  in  the  envelopment  of  IMV.  Perhaps  the 
yeast  two-hybrid  system  could  be  used  to  identify  protein 
partners  in  the  process  of  IMV  envelopment. 
Although  the  work  presented  in  this  thesis  solves  a  number 
of  scientific  problems,  it  provides  the  basis  for  additional 
research  that  is  perhaps  of  greater  biological  significance.  Using 
this  work  as  a  foundation,  scientists  may  now  address  the 
problem  of  protein  palmitylation  by  a  directed  approach.  The 
information  provided  here  should  allow  the  identification  of  new 
palmitylproteins  and  narrow  the  search  for  their  sites  of 
modification.  Only  then  can  the  biological  role  of  the  modification 
be  ascertained. 105 
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